Thrombosis and Haemostasis

Blood coagulation and beyond: Position paper from the Fourth Maastricht Consensus Conference on Thrombosis

Cengiz Akbalut, Ryanne Arisz, Constance Baaten, Gaukhar Baildildinova, Aarazo Barakzie, Rupert Bauersachs, Jurriën M ten Berg, Wout van den Broek, Hetty C de Boer, Vanessa Broker, Richard Buka, Hugo ten Cate, Arina t Cate, Ciro De Luca, Ilaria De Simone, Françoise Dignat-George, Kathleen Freson, Giulia Gazzaniga, Eric van Gorp, Anxhela Habibi, Yvonne M.C. Henskens, Aaron F Iding, Abdullah Khan, Gijsje Koenderink, Akhil Konkoth, Romaric Lacroix, Trisha Lahiri, Wilbur Lam, Rachel Lamerton, Roberto Lorusso, Qi Luo, Coen Maas, Owen J. T. McCarty, Paola van der Meijden, Joost Meijers, Adarsh Mohapatra, Neta Nevo, Alejandro Pallares Robles, Philippe Poncelet, Christoph Reinhardt, Wolfram Ruf, Ronald Saraswat, Claudia Schonichen, Roger E Schutgens, Paolo Simioni, Stefano Spada, Henri M Spronk, Karlygash Tazhibayeva, Jecko Thachil, Rocio Vacik-Diaz, Alicia Veninga, Peter Verhamme, Chantal Visser, Steve P Watson, Philip Wenzel, Ruth Willems, Anne Willers, Pengyu Zhang, Konstantinos Zifkos, Anton-Jan van Zonneveld.

Affiliations below.

Abstract:
The 4th Maastricht Consensus Conference on Thrombosis (MCCT), included the following themes:
Theme 1: The "coagulome" as a critical driver of cardiovascular disease
Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow and kidney. Four investigators shared their views on these organ-specific topics.

Thieme

Theme 2: Novel mechanisms of thrombosis

Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infections associated-coagulopathies perturb the hemostatic balance resulting in thrombosis and/or bleeding.

Theme 3: How to limit bleeding risks: insights from translational studies

This theme included state of the art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed.

Theme 4: Hemostasis in extracorporeal systems: how to utilize ex vivo models?

Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularised organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation (ECMO) associated coagulopathy are discussed.

Theme 5: Clinical dilemmas in thrombosis and antithrombotic management

Plenary presentations addressed controversial areas, ie thrombophilia testing, thrombosis risk assessment in hemophilia, novel antiplatelet strategies and clinically tested factor XI(a) inhibitors,both possibly with reduced bleeding risk. Finally, Covid-19 associated coagulopathy is revisited.

Corresponding Author:

Prof. Hugo ten Cate, Maastricht University Medical Centre+, Thrombosis Expert Center and departments of Internal medicine and Biochemistry, Maastricht, Netherlands, h.tencate@maastrichtuniversity.nl

Affiliations:

Cengiz Akbalut, Maastricht University Cardiovascular Research Institute Maastricht, Biochemistry, Maastricht, Netherlands

Ryanne Arisz, Erasmus MC, Haematology, Rotterdam, Netherlands

Constance Baaten, Maastricht University Medical Center, Maastricht University Medical Center, Maastricht, Netherlands

[...]

Anton-Jan van Zonneveld, Leiden University Medical Center, Nephrology Department, Leiden, Netherlands

Thieme

Blood coagulation and beyond: Position paper from the Fourth Maastricht Consensus Conference on Thrombosis

Asim Cengiz Akbulut[1], Ryanne A. Arisz[2], Constance C.F.M.J. Baaten[1,3], Gaukhar Baidildinova[1,4], Aarazo Barakzie[2], Rupert Bauersachs[5], Jur ten Berg[6], Wout W.A. van den Broek[20], H.C. de Boer[7], Amandine Bonifay[8,9], Vanessa Bröker[1,4], Richard J Buka[10], Hugo ten Cate[1,4,11], Arina J ten Cate-Hoek[11], S. Cointe[8,9], C. De Luca[21], Ilaria De Simone[1], Rocio Vacik Diaz[4,8], Françoise Dignat-George[8,9], Kathleen Freson[13], Giulia Gazzaniga[6,14], Eric C. M. van Gorp[15], Anxhela Habibi[1], Yvonne M.C. Henskens[16], Aaron F.J. Iding[1,11], Abdullah Khan[10,17], Gijsje H. Koenderink[18], Akhil Konkoth[1,8], Romaric Lacroix[8,9], Trisha Lahiri[4,8], Wilbur Lam[19], Rachel E Lamerton[10], Roberto Lorusso[6], Qi Luo[1], Coen Maas[22], Owen J.T. McCarty[23], Paola E.J. van der Meijden[1,11], Joost C.M. Meijers[24,25,26], Adarsh K Mohapatra[1,3,8], Neta Nevo[27,28], Alejandro Pallares Robles[1,4], Philippe Poncelet[31], Christoph Reinhardt[4], Wolfram Ruf[4], Ronald Saraswat[4,8], Claudia Schönichen[1,4],Roger Schutgens[29], Paolo Simioni[30], Stefano Spada[1,4], Henri MH Spronk[1,11], Karlygash Tazhibayeva[12], Jecko Thachil[32], Rocio Vacik Diaz[4,8], L Vallier[8], Alicia Veninga[1], Peter Verhamme[33], Chantal Visser[2], Steve P Watson[10], Philip Wenzel[4], Ruth AL Willems[1], Anne Willers[6], Pengyu Zhang [1,34], Konstantinos Zifkos[4], Anton Jan van Zonneveld[7]

1: Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
2: Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
3: Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany

4: Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Johannes Gutenberg-University Mainz, 55131 Mainz, German Center for Cardiovascular Research (DZHK), Partner Site Rhein-Main, Germany

5: Cardioangiologisches Centrum Bethanien – CCB, Gefäß-Centrum; Frankfurt am Main

6: Department of Cardio-Thoracic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands

7: Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands

8: Aix-Marseille University, C2VN, INSERM 1263, INRAE 1260, Marseille, France

9: Department of Hematology and Vascular Biology, CHU La TIMONE, APHM, Marseille, France

10: Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Birmingham, U.K, B15 2TT

11: Thrombosis Expertise Center, Maastricht University Medical Center, Maastricht, the Netherlands

12: Al Farabi Kazakh National University, Almaty, Kazakhstan

13: Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium

14: Department of Clinical-Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy.

15: Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands

16: Central Diagnostic Laboratory, Unit for Hemostasis and Transfusion, Maastricht University Medical Centre+, Maastricht, The Netherlands.

17: MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine and National Institute of Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, U.K. OX3 9DS

18: Department of Bionanoscience, Kavli Institute of Nanoscience Delft, Delft University of Technology, Delft, The Netherlands

19: Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States.

20: Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands

21: Laboratory of Morphology of Neuronal Networks and Systems Biology, Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", 80138 Napoli, Italy.

22: CDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

23: Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA

24: Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands

25: Amsterdam UMC, University of Amsterdam, department of Experimental Vascular Medicine, Amsterdam, The Netherlands

26: Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, The Netherlands

27: Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

28: Department of Immunology, Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel.

29: Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, UMC Utrecht, University Utrecht, Utrecht, The Netherlands

30: General Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Padua University Hospital and University of Padua Medical School, Padua, Italy

31: R and T Department, BioCytex, Marseille, France

32: Department of Haematology, Manchester University Hospitals, Manchester, UK.

33: Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

34: Leibniz Institute for Analytical Sciences - ISAS-e.V., Dortmund, Germany

Abstract

The 4th Maastricht Consensus Conference on Thrombosis (MCCT), included the following themes.

Theme 1: The "coagulome" as a critical driver of cardiovascular disease

Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow and kidney. Four investigators shared their views on these organ-specific topics.

Theme 2: Novel mechanisms of thrombosis

Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infections associated-coagulopathies perturb the hemostatic balance resulting in thrombosis and/or bleeding.

Theme 3: How to limit bleeding risks: insights from translational studies

This theme included state of the art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control

the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed.

Theme 4: Hemostasis in extracorporeal systems: the value and limitations of ex vivo models

Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularised organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation (ECMO) associated coagulopathy are discussed.

Theme 5: Clinical dilemmas in thrombosis and antithrombotic management

Plenary presentations addressed controversial areas, ie thrombophilia testing, thrombosis risk assessment in haemophilia, novel antiplatelet strategies and clinically tested factor XI(a) inhibitors,both possibly with reduced bleeding risk. Finally, Covid-19 associated coagulopathy is revisited.

Introduction

During the 4th Maastricht Consensus Conference on Thrombosis (MCCT), held in April 2022, the main Theme of the conference was "Blood coagulation and beyond" expressing the desire of the organizers to look beyond boundaries. A characteristic of this conference is the strong interaction among presenters and audience encouraged by the breakout sessions following presentations creating room for in depth discussions among basic, translational and clinical scientists from different backgrounds. The MCCT meeting focused on 5 different topics, to be addressed below. The authors comprise not only faculty but also PhD students that were actively involved in discussions as well as note taking of the discussion sessions; these notes and the summary of the presentations provided the basis for this article in which all actively

involved act as contributory author. This meeting was co-organized with the EU- Marie Curie International Training Network Ticardio and all PhD students from this network were contributing to this paper.

Theme 1: The "coagulome" as a critical driver of cardiovascular disease

The brain coagulome

To briefly introduce the term coagulome, which we use in analogy of the previously used term "endotheliome" to describe a multifactorial approach to the endothelium (PMID: 21168189), assessing its multifunctional properties in health and disease by combining different methods, to obtain an integrated image this pivotal cellular compartment.

Primary and secondary prevention of ischemic stroke benefits from antiplatelet and anticoagulant therapies (1). However, compared to coronary heart diseases, P2Y12 inhibitors other than clopidogrel have no clinical use in primary stroke prevention and can be contraindicated (prasugrel) in patients with a previous stroke for increased risk of intracranial bleeding (2). Similarly, dual antiplatelet therapy is effective just in the early phases of the ischaemic stroke (21-30 days) before becoming useless or detrimental. In the case of Vorapaxar, which is the only approved drug of a novel class antithrombotic agent acting on the protease-activated receptor-1 (PAR-1), trials directly assessing stroke management are lacking (3). PAR-1 is fundamental for pleiotropy of coagulation factors in the CNS (4). The main proteases that can activate PAR-1 are matrix metalloproteinase 9 (MMP-9) (4) and thrombin, whose activation state, concentration, and association with activated protein C (aPC) leads to differential pathway activation in physiology (5) as well as CNS pathologies. Factor (F) XI has been shown to be involved in thrombus stabilization during stroke (6). In a large population elevated FXI was associated with risk of ischaemic stroke and a FXI:C level < 15U/dL incurred protection against stroke (7), (8). The FXIa level was higher in subjects

Accepted Manuscript

with previous stroke compared with those with a history of transient ischaemic attack (TIA) (34% vs 11.4%, p < 0.0001), suggesting that FXIa is associated with worse functional outcomes of cerebrovascular disease (9). The related mechanism could be that inhibition of FXI(a) reduces thrombin generation, activation of TAFI (thrombin activatable fibrinolysis inhibitor) and ultimately may enhance the lysis of clots that form or embolize into cerebral arteries.

Consistent with those findings in human studies, in the mouse model of acute ischaemic stroke (temporal occlusion of the middle cerebral artery), administration of antibody 14E11 that blocks the FXIIa dependent activation of FXI resulted in a significant reduction in infarct size and a significant improvement in neurological function compared with the control group (10). Clinical and experimental evidence demonstrated that coagulation proteins have pleiotropic effects on the central nervous system (CNS) not limited to physiological repair of vascular damage and pathological ischaemic/haemorrhagic stroke.

The different effects of antiplatelet and anticoagulant agents on the CNS can be in part due to the existence of a unique and complex interface represented by the neurovascular unit (NVU). Indeed other organs can promptly differentiate their own blood vessels when repairing a lesion, or for metabolic reasons even without perturbing the tissue integrity, the same cannot be said for the CNS. The NVU is a unique integrated frontier in which the mesenchymal cells (endothelial cells, pericytes, smooth muscle cells, fibroblasts) do not originate from within the CNS tissue (purely ectodermal formed by neurons and macroglia) but penetrate without violating its integrity during embryogenesis. During CNS development through a clear contribution of coagulation factors such as tissue factor pathway inhibitor (TFPI), FV, FVII, and FX, the mesenchyma enters the nervous parenchyma (11). The same happens for the resident immune cells, the microglia, which is a distinct population of myeloid cells, not differentiated from the bone marrow, but originating from the yolk sac

(12). Hence the coagulation factors, as mentioned, do not limit their intervention to vascular repair and exert their function also on the nervous tissue, justifying their emerging role in neurological diseases other than stroke.

This pleiotropy has been demonstrated in various pathologies that have no strict vascular etiology, such as multiple sclerosis (MS), Parkinson's disease (PD), and Alzheimer's disease (AD) (4). TFPI was shown to be increased in the frontal cortex of AD brains compared to healthy controls (13). In multiple sclerosis (MS) patients, TFPI levels were higher in the group of progressive MS compared to relapsing-remitting MS and healthy controls. Same results were obtained for PAI-1 expression in these groups (14). In a randomized controlled trial of recovering MS patients, it was shown that plasma levels of TFPI (15) and other coagulation inhibitors (e.g. protein S) increased with increasing recovery rate and patients with a generally low level of TFPI in earlier disease states showed better rehabilitation afterwards (15).

As a neurodegenerative disease, Alzheimer's disease (AD) is characterized by abnormal loss of cholinergic neurons in areas of the brain that are primarily responsible for cognition and memory. The key pathological elements in AD have been proven to be amyloid-β (Aβ) peptides and neurogenic fiber tangles (NFTs). In animal studies, human amyloid precursor protein (hAPP) transgenic mice from line J20 (hAPP-J20 mice) are used to establish the AD model, and the results have shown that coagulation factors are involved in the metabolism of Aβ (16), (17), which can lead to the activation of FXII, resulting in FXI activation and thrombin generation, ultimately leading to a prothrombotic environment that contributes to the development of AD. These data are supported by decreased levels of plasmatic FXI in AD patients, with depletion of its inhibitor, suggesting a chronic activation with subsequent inactivation and clearance of FXI during the disease (18). Moreover, in the same patients, activation of the intrinsic coagulation pathway is supported by elevated plasmatic fibrin

levels (18). Compared to cognitively healthy people or patients diagnosed with mild cognitive impairment, patients who are diagnosed with AD have significantly increased plasmatic levels of FXI (19). FXI may therefore be a predictor of AD-type diagnosis, as an increase in FXI has been associated with a reduction in cognitive function (19,20). Proteomic analyses of plasma and post-mortem brain tissues (the inferior frontal cortex, superior frontal cortex, and cerebellum) from AD patients, demonstrated a clear activation of complement coagulation cascade, in particular of FXII and FXIII, further corroborating this hypothesis. The pathogenesis of AD could be particularly sensitive to NVU disruption; fibrin deposition, possibly an end stage product resulting from the long-term dysfunction of the NVU, has been demonstrated in both large vessels and capillaries of AD patients and can have a great impact on metabolic coupling, particularly in the hippocampal region (21). Parenchymal deposition of fibrin, as the last step of the coagulation cascade, could enhance the inflammatory state and contribute to the loss of integrity of the blood-brain barrier (BBB). In the dysfunctional NVU, astrocytic Apolipoprotein E4 (APOE4), interacting with pericytic low-density lipoprotein receptor-related protein 1 (LRP1), through cyclophilin A (CypA) signaling, increases MMP-9 transduction and thrombin/PAR-1 signaling (22). The BBB breakdown was more severe in carriers of APOE4, an identified genetic risk factor for AD with cognitive impairment, independently of AD biomarkers, both amyloid-β (Aβ) and tau. The BBB damage, measured in vivo by MRI as well as pericyte- and platelet-derived biomarkers such as soluble platelet-derived growth factor receptor β (sPDGFRβ) predicted the future cognitive status in carriers even after controlling the analysis for Aβ and tau levels (22). These predictive biomarkers correlated with increased CypA - MMP9 activity in the cerebrospinal fluid (CSF) and are very promising for early diagnosis of AD. Fibrin-Aβ fibrils are not accessible to breakdown by plasmin, activate FXII and inhibit microglia/macrophages scavenging through CD11b silencing (23). Blockage of fibrin-Aβ interaction (as

demonstrated through RU-505) could pave the way to overcome the failures in disease-modifying therapies for neurodegeneration (24). Finally, FXIIa, high molecular-weight kininogen (HK), and kallikrein activities, all thrombo- inflammatory mediators, are detected in AD and their effects can be experimentally attenuated by FXII depletion (25).

The aforementioned data reinforce the idea of the vicious circle starting with the regional failure of the NVU and leading to protein deposition and neuroinflammation.

Potential areas for future investigation:

- Investigate the emerging pleiotropic role of coagulation cascade in the CNS with the central role of PAR1 interference.
- Explore the role of pericytes for NVU stability, for vascular tone, permeability, and metabolic regulation and as early CSF biomarkers of Alzheimer's disease.
- Search for brain-specific biomarkers of the patient's thrombo-inflammatory state to develop non-invasive, easy to access diagnostic/prognostic tools.
- Diffuse homogeneous protocols for the evaluation of BBB integrity using standard MRI or PET-CT scans, to be correlated with novell biomarkers (e.g. sPDGFRβ) and ATN (Amyloid, Tau, Neurodegeneration) classification in clinical settings.
- Targeting the fibrin/CD11b complex and inhibiting FXIa and FXII with novel or existing drugs in future clinical trials for neurodegeneration, especially AD.

The cardiovascular coagulome: Focus on thrombin and inhibition of its amplification

While the role of thrombin generation in coronary heart disease, including the process of atherogenesis and atherothrombosis, has been demonstrated in experimental and clinical

studies, current research focuses on specific coagulation proteases, including FXI and the tissue factor (TF) /TFPI axis.

Factor XI, as a component of the intrinsic pathway of coagulation, is activated by FXIIa and then proceeds to the downstream coagulation cascade that eventually triggers thrombin generation. In addition, FXI can also be feedback activated by thrombin, further accelerating fibrin formation. Over the past decades, many studies have attempted to investigate the role of FXI in thrombin generation and its relationship with thrombus formation.

In the animal model of atherosclerosis (ApoE knockout mice, ApoEko), knockout of FXI reduced peripheral atherosclerosis by up to 33% (26), (27). In another animal study, low-density lipoprotein receptor knockout (Ldlr$^{-/-}$) mice combined with high-fat diet (HFD) were treated with anti-FXI antibody (14E11) or FXI ASO. Compared to controls, 14E11 and FXI-ASO both reduced the area of atherosclerotic lesions in the proximal aorta, and 14E11 also reduced aortic sinus lesions (28). These data suggest that FXI plays a role in atherogenesis, and that depletion of FXI may reduce development of atherosclerosis. Another indicative factor for thrombogenicity in coronary lesions might be the co-localization of TFPI with TF. Tissue studies of coronary atherosclerotic plaques revealed expression of TFPI in endothelial cells, macrophages, foam cells, and smooth muscle cells. Co-localization with TF only occurred in endothelial cells and macrophages in the groups of highest severity and was also found in the necrotic lipid core (29).

Coronary heart disease (CHD) is the result of partial or complete occlusion of the coronary arteries due to thrombosis, which impairs the blood supply to the heart muscle. Outcomes of the PRIME study including nearly 10,000 men showed that patients with a general low free TFPI plasma concentration had a more than 2-fold increased risk of developing CHD. This effect was increased to 7-fold, when vWF levels were increased (30). Additionally, TFPI levels were generally higher in non-ST segment elevation myocardial infarction (NSTEMI)

compared to STEMI patients (31). In another study, TFPI levels in hospitalized patients with acute coronary syndrome were indicative for the severity of myocardial infarction but were not associated with mortality (32).

Numerous polymorphisms of TFPI have been studied over the last decades that in part correlate with increased risk of cardiovascular disease (33); (34), but sometimes only show to be related to altered TFPI plasma levels, but not to an increased risk for CHD (35–37). However, studies reporting blood concentrations of coagulation should be carefully interpreted, since lower circulating levels could reflect both reduced production or increased consumption (or vice versa). This requires more research to understand the pathophysiology in the respective disease setting to improve applicability of a given coagulation factor as a putative biomarker.

Lorentz et al. found that mice treated with an anti-FXI antibody, 14E11, had decreased myocardial infarct size in a model of ischaemia/reperfusion (I/R) injury, indicating that FXI activation or activity might contribute to cardiac I/R injury (38). Kossmann et al. revealed that depletion of FXI could not only decrease a vascular coagulation-inflammatory circuit in angiotensin II-induced arterial hypertension but also prevent arterial hypertension-induced end-organ damage (39).

The role of FXI in acute myocardial infarction (AMI) is less clear than in stroke. Patients with lower levels of FXI are at less risk of VTE and MI (40) and FXI level is correlated with MI risk among men in the study of Myocardial Infarction Leiden (41). Butenas et al. reported that plasma FXIa level could be quantified in most patients with acute coronary syndromes, whereas it was undetectable in age-matched healthy controls (42). However, conflicting data exist. Salomon et al. reported similar incidences of AMI in patients with severe FXI deficiency and the general population and inherited FXI deficiency seems to be not protective

against AMI (43). Results from the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Case-Control Study showed that high levels of FXI are associated with ischemic stroke (IS), but are not or to a lesser extent associated with MI, in young women (44). These data suggest that the contribution of FXI in thrombosis varies between vascular beds and sex. The question why the deficiency of FXI has disparate effects on acute IS and MI, and what the exact role of FXI on MI is, still requires further exploration.

Atrial Fibrillation (AF) is the most common sustained cardiac rhythm disorder and is associated with a prothrombotic state. It was shown in a cohort study that in long-term follow-up, FXIa level in circulating blood has been associated with poor prognosis such as IS and cardiovascular death in AF patients on anticoagulants (45). Recently, the FXIa inhibitor asundexian at two doses (20 and 50mg daily) showed lower bleeding rates than the active comparator, the FXa inhibitor apixaban 5mg, in a phase II trial in AF at risk for stroke. However, it still remains to be further investigated to what extent inhibition of FXI(a) is equally or more effective than established direct oral anticoagulants (DOACs) to prevent thrombotic events and if they could improve long-term prognosis of AF (46). Current clinical studies testing the efficacy and safety of different types of FXI inhibitors, or FXI lowering agents, is discussed further on in this article.

Potential areas for future investigation:

- A possible therapeutic target to prevent thrombo-inflammation occurring in the heart is the direct targeting of FXI or FXII that both can bind to platelets that concentrate both factors through their GPIbα and PAI-1 surface proteins and thereby increasing thrombin generation. A potential drawback of targeting in particular FXII is the increased risk for infection. Patients that are receiving FXI/FXII inhibitor treatment

should therefore be monitored on a regular basis for markers of infection or inflammatory disease, such as concentration of complement fragment C1q in soluble plasma.

● It remains to be investigated in clinical trials, what exactly the differences are between inhibition of FXI and FXII and whether there is any redundancy to targeting prekallikrein. Also, potential mechanisms of bypassing FIX activation should be elucidated beforehand.

● It is still unclear whether possible therapeutic options against cardiovascular thrombosis would also be suitable for treating or preventing thrombotic events in the management of aortic valve stenosis. One major risk factor for aortic valve stenosis patients is acquired von Willebrand factor (vWF) syndrome, which is directly related to disease severity. In this condition, vWF becomes proteolytically cleaved by high shear forces as it passes the stenotic valve. This results in a higher bleeding risk for patients of aortic valve stenosis that is not easy to measure.

● Another possible treatment strategy for preventing hypercoagulation in the heart might be drugs targeting TF or FVII, but to avoid bleeding, a safer approach is the targeting of TF signaling pathways. Also, inhibitors of TF/FVII, such as NAPc2, could be repurposed as anti-inflammatory or anti-fibrotic drugs.

Bone marrow: role of coagulation in cell trafficking

Following haematopoietic stem cell transplantation (HSCT), the blood and immune system take a long time to regenerate. This period is dangerous since patients have a low ability to mount an immune response and are at a high risk for life threatening infections and internal bleeding. Therefore, finding novel ways to shorten the recovery time will reduce morbidity

and mortality rates post HSCT. Previously the role of coagulation-associated pathways in regulation of murine haematopoietic stem and progenitor cells (HSPC) maintenance within the bone marrow (BM) has been described (47), (48), (49). (add doi: 10.1182/blood-2017-12-768986; doi: 10.1038/nm.3960) Importantly, these pathways also regulate the mobilization of human HSPC in healthy stem cell donors, and moreover, impact the neutrophil and platelet engraftment rates of patients post HSCT (50). In particular, the involvement of PAR1, the major thrombin receptor in human HSPC regulation was shown through analysis of peripheral blood (PB) samples obtained from 20 healthy HSPC donors before and after treatment with G-CSF. Overall, the baseline levels of PAR1 expression on circulating mononuclear cells (MNC) before G-CSF treatment positively correlated with higher yields of total G-CSF mobilized leukocytes and CD34+ HSPC. To further assess the requirement for functional PAR1 signaling in human HSPC mobilization, chimeric immune-deficient mice were utilized, pre-engrafted with human cord blood HSPC. Importantly, blocking PAR1 signaling by in vivo administration of a specific PAR1 antagonist inhibited G-CSF induced mobilization of human white blood cells (WBC) and CD34+ HSPC to the circulation of chimeric mice. Migration, homing, engraftment and mobilization of human HSPC is dependent on the chemokine CXCL12, which is highly expressed in the BM, and its major receptor CXCR4, which is expressed by human HSPC. Importantly, in vitro migration of human HSPC towards a gradient of the chemokine CXCL12 was inhibited by blocking PAR1, suggesting a role in human HSPC migration and engraftment. Indeed, by following recovery parameters of patients transplanted with G-CSF-mobilized cells, accelerated neutrophil and platelet engraftment in patients transplanted with mobilized cells expressing higher PAR1 levels on MNC at baseline was demonstrated. Utilizing functional preclinical murine models, the importance of the thrombin/PAR1/nitric oxide (NO) axis as a crucial regulatory pathway mediating G-CSF-induced mobilization was demonstrated (51). The most

primitive, BM retained, long-term repopulating haematopoietic stem cells (HSC) express endothelial protein C receptor (EPCR). Its major ligand, activated protein C (APC), is also produced in the BM. Signaling via the APC/EPCR/PAR1 axis controls BM HSC adhesion and retention via NO inhibition and activation of adhesion interactions. Contrary, G-CSF activates NO generation in HSPC, EPCR shedding from their surface, which leads to their mobilization. Importantly, EPCR expression is essential for chemotherapy resistance of normal mouse (49) and human HSC (52) via adhesion interactions suggesting that, unfortunately, EPCR also protects human AML stem cells from radio and chemotherapy treatment. To conclude, Nevo and colleagues identified a new player participating in regulation of human HSPC, with potential to predict efficiency as well as clinical outcome of G-CSF-induced mobilization, homing, and engraftment kinetics as well as efficiency.

Potential areas for future investigation:

● Assess the clinical importance of PAR1 by validating its role in autologous HSPC transplantation setting, where the main difficulty is harvesting mobilized HSPC from heavily chemotherapy treated patients.

● Manipulating PAR1 expression in human HSPC to improve the efficiency of mobilization and prognosis of HSPC transplanted patients.

● Analyze the role of coagulation proteases in G-CSF-induced mobilization.

Kidney: the coagulome in kidney disease

The loss of the microvasculature, also referred to as microvascular rarefaction, is a critical determinant in kidney disease states such as acute kidney failure, diabetic nephropathy or kidney transplant rejection (53). The resulting ischaemia is a driver for an inflammatory

response that is associated with increased expression of pro-fibrotic mediators such as TGFβ or CTGF (Connective Tissue Growth Factor; CNN2) that ultimately contribute to chronic kidney failure. Pericytes are essential functional components of the microvasculature stabilizing the capillaries through multiple reciprocal interactions. A key mechanism in microvascular rarefaction is the dissociation of pericytes from the capillary endothelial cells (EC) (54) subsequent to inflammatory or pro-angiogenic stimuli (55) such as TNFα, VEGF or a dysbalance in the circulating levels of angiopoietin(ang)-2 over ang-1 (56). Conditions associated with ischemia can rapidly upregulate TF expression by vascular EC and elicit a pro-coagulant response through activation of the endothelial PARs. As a consequence, activated EC lose their cell-cell contacts, dissociate from the pericytes and engage in an angiogenic response, all processes that can promote microvascular rarefaction. For instance, in AF, the disbalance between supply and the excessive need for oxygen by the fibrillating myocytes leads to a state of hypoxia[5] that promotes subendothelial TF expression. Therefore, a role for the coagulome in the microvascular rarefaction that drives the pro-fibrotic substrate for AF is under active investigation. For instance, a recent paper by Dolleman et al. explored the impact of DOACs on vascular integrity in vitro using platelet-free plasma in thrombin generation- and endothelial barrier assays (57). Interestingly, they demonstrated that while the anti-FXa DOAC rivaroxaban and the anti-thrombin DOAC dabigatran are both efficient in blocking their target proteases, rivaroxaban could preserve endothelial barrier function while dabigatran failed to protect endothelial integrity. The barrier disrupting effect of dabigatran could be prevented in the presence of a custom-made peptide that blocks thrombin's exosite-I. The take home message of this study is that selective use of DOACs could well have a favorable impact on long term (micro-)vascular health.

Many studies have shown that activation of the coagulation system and platelets go hand in hand. In mouse models of kidney ischemia/reperfusion injury platelets rapidly adhere to the ischaemic (micro-)vasculature. Using an in vitro model, it was demonstrated that platelets predominantly adhere to the (TF rich) EC matrix where gaps were formed resulting from the loss of EC-EC contacts in cultured monolayers (**Figure 1**). Using this model of perfusion of platelet rich plasma it was demonstrated that the adhered platelets markedly stimulated the generation of FXa depending on the presence of phospholipids, TF and TFPI (Dolleman et al. manuscript in preparation). Subsequent studies revealed that the adhered platelets resemble so-called coated platelets (58) that, due to dual activation, highly express P-selectin, TF, TFPI and heparinase. These data strongly support a potential role for platelets in ischaemia driven microvascular rarefaction. This could be particularly relevant for patients with diabetic nephropathy. In fact, recent data show that platelets can be detected in the glomeruli of patients with diabetic kidney disease. Moreover, a direct relation was observed between platelet-derived extracellular vesicles and the degree of albuminuria in these patients (59). Subsequent mechanistic studies in a mouse model for diabetic nephropathy demonstrated that the platelet P2Y12 inhibitor ticagrelor could counteract disease progression by lowering albuminuria, mesangial matrix expansion, macrophage infiltration and fibrosis (60). Future studies with selective platelet inhibitors such as GLP-1 analogues (61) could well augment our therapeutic options in progressive ischemia-associated diseases of the kidney.

Potential areas for future investigation:

● While equally effective in anticoagulant activity, selective use of DOACs could have long term beneficial effects for microvascular complications in CKD patients. These in vitro findings should be validated by in vivo animal and clinical studies.

● The long term benefit of the use of selective platelet inhibitors by patients with

 diabetic nephropathy warrants clinical investigation.

Figure 1

Platelet-rich plasma rotation perfusions on TNFα-treated monolayers of human umbilical

vein endothelial cells. After 15 minutes the cultures were fixed and stained for platelets (F-

actin), nuclei

(Hoechst) and (right panel) fibrin (anti-fibrinogen antibody). A: Platelets selectively

adhere to the extracellular matrix exposed in gaps that appeared between the endothelial

cells upon overnight exposure to TNFα. Subsequent analyses demonstrated the platelets

display all characteristics of "coated platelets". B: Fibrin fibers confirm the activation of

the coagulation system at the site of platelet adhesion.

Coagulation in endothelial cell barrier function

Hyperlipidemia results in LDL/APOB-containing lipoprotein accumulation in the artery walls, promoting vascular inflammation, endothelial cell dysfunction, localized loss of endothelial barrier function. Recent works has highlighted the extensive crosstalk between coagulation and inflammation in such diseases in which endothelial cell dysfunction serves as a hallmark. (62–66). Yet, the inciting factors for inflammation in hyperlipidemia remain unclear. Studies have shown that inhibiting FXI reduced inflammatory markers in mouse and non-human primate models of either acute and chronic inflammation.(cite PMID: 27046148 , 33598692, 33421301 , 30808684) Translating this to patients, it has recently been shown that pharmacological inhibition of FXI reduces inflammatory markers, including the hallmark biomarker C-reactive protein (CRP), in a clinical trial in end-stage renal disease patients on hemodialysis (PMID:34086880) Follow-on studies are underway to evaluate whether use of FXI inhibition for the prevention of catheter-associated thrombosis similarly blunts the rise in CRP levels following placement of an indwelling catheter, which would provide further evidence of a link between the FXI activation and inflammation (ClinicalTrials.gov #NCT04465760). Continuing this theme, preliminary studies in a primate model of diet-induced hyperlipidemia show that the elevated CRP levels in an obese cohort were reduced by ~25% following 4-weeks of anti-FXI therapy. Defining the mechanisms by which FXI plays a role in propagating inflammation will provide insight into whether FXI inhibition has potential therapeutic anti-inflammatory benefits in cardiovascular disease and in particular, hyperlipidemia.

Vascular endothelium serves as a site of catalysis for enzymatic reactions, while also facilitating multiple pathways that maintain blood cells in a quiescent state. As such,

endothelial cell dysfunction is common in inflammatory diseases, such as atherosclerosis, and often appears early on in the course of the disease (68,69). Recent observations have shown that FXI inhibition preserves endothelial barrier function in mice and primates in vivo (28,70), suggesting that the EC surface may serve as a source or a sink for FXIa activity (Figure 3). Mechanistic studies discovered that the anticoagulant role of the endothelium includes sequestration of FXIa activity (71). Next, it was determined that FXIa is inactivated by complex formation with vascular endothelial cell-derived plasminogen activator inhibitor-1 (PAI-1). It was found that FXIa-PAI-1 complexes were either released into the media or trafficked to EC endosomes and lysosomes in vitro (Figure 3). In a nonhuman primate model of lethal systemic inflammatory response syndrome associated with sepsis, the authors were able to detect FXIa–PAI-1 complexes in the circulation after a bacterial challenge (71). In preliminary studies, it was found that inactivation of FXIa by PAI-1 on the EC surface may invoke a signaling pathway to increase vascular permeability by way of cleavage of endothelial cell VE-cadherin. Taken together, this data suggests that the kallikrein-kinin system, and, in particular, FXI, acts as a nexus between the coagulation cascade, inflammation, and endothelial cell barrier function. This work holds promise to provide rationale for FXI inhibition as a useful approach for protecting barrier function in settings characterized by inflammation such as hyperlipidemia.

Figure 3

Endothelial cells promote the activation of the kallikrein-kinin system while inhibiting FXIa activity.

Potential areas for future investigation:

- To determine whether the ability of FXI to act 'upstream' and activate FXII contributes to activation of the kallikrein-kinin system to promote inflammation.

- To explore if FXI activation or activity directly regulates endothelial cell barrier (dys)function.

The relevance of factor XII?

Activated factor XII (FXIIa) is a serine protease consisting of a heavy and a light chain held together by a disulfide bond. It auto activates upon contact with negatively charged compounds (e.g. glass, kaolin and diatomaceous earth), as well as biological negatively

charged molecules (e.g. DNA, RNA, misfolded proteins, polyphosphates). Substrates of

FXIIa include proteins involved in coagulation, inflammation, fibrinolysis, and angiogenesis.

Surprisingly, however, its deficiency in humans has not been associated with an overt

pathological phenotype. Nevertheless, a cohort study found FXII levels to be inversely

associated with overall mortality, although not for those at the lowest levels (72). These

apparently contradictory findings have stirred the debate on the physiologic functions of FXII

(**Figure 4**).

Insert figure

Involvement of FXII in human hemostasis is based on its essential role in contact-activated in

vitro coagulation assays. Moreover, its concentration in blood is higher than any other

coagulation factor from the contact activation system (e.g. about 10-fold higher than FXI).

This stands in stark contrast to the lack of a bleeding phenotype in FXII-deficient humans and

knockout mouse models. Thus, the question arises: is FXII really a coagulation factor? To

explain this discrepancy, it has been hypothesized that FXII might only be involved in

hemostasis of soil-contaminated wounds, where it is activated by negatively charged silicates.

This so-called "dirty wound theory" is based on the observation that marine animals lack

FXII, in contrast to land-based animals (73). From an evolutionary perspective, particularly

the absence of FXII in sea mammals suggests its redundancy in wounds which are

continually cleaned by surrounding water. This theory is supported by experiments in FXII-

knockout mice, where hemostatic differences between clean and soil-contaminated wounds

were observed (74). Future studies will have to establish if these differences also have

physiological relevance in humans.

While its haemostatic role in wound healing remains uncertain, activated FXII is known to

trigger the formation of kallikrein and bradykinin release, which stimulates vasodilation,

vascular permeability, neutrophil migration and complement activation contributing to the immune defense in the wound site. Interestingly, excess FXIIa levels are observed in a genetic disease called hereditary angioedema (HAE), characterized by recurrent episodes of severe edema due to extreme bradykinin release (75). It is caused either by a FXII mutation causing increased autoactivation or a deficiency of its main inhibitor, C1 esterase inhibitor (76). Another mutation of FXII resulting in spontaneous auto-activation has been identified as the cause of a rare disorder termed FXII-associated cold autoinflammatory syndrome (FACAS), which is characterized by cold-induced urticaria, arthralgia, chills, headaches, and malaise (77). These phenotypes of HAE and FACAS both support the notion that FXII is mainly involved in regulating inflammation and vascular permeability.

Notably, patients with HAE or FACAS are not reported to have increased thrombosis risk, despite the underlying uncontrolled FXII activation. This begs the question: can FXIIa "choose" to have enzymatic activity for a certain substrate? Unraveling of this question will require further molecular insight into FXII. Currently, this protein is thought about as a "string of pearls" with five domains linked to the protease domain by a proline-rich region. However, the natural confirmation of FXII is most likely very different and our understanding of individual domains is limited. Molecular research will have to establish in what ways this protein can be activated and interact with its substrates, which might explain distinct enzymatic activity in different conditions.

Furthermore, FXII has been implicated in the fibrinolytic system based on its high degree of homology with tissue plasminogen activator (tPA). Indeed, in vitro experiments have shown that FXIIa can convert plasminogen to plasmin and enhance fibrinolysis, but its rate is much lower than that of tPA or urokinase plasminogen activator (uPA) (78). Therefore, the

relevance of this enzymatic activity in vivo remains to be established. Conversely, however, plasminogen was found to influence pathways of FXII presenting as HAE in the setting of a rare plasminogen mutation (HAE-PLG) (79).

Finally, although FXII is mainly secreted by the liver, there is growing evidence for a separate pool of leukocyte-expressed FXII that contributes to wound healing and angiogenesis (80). This was found to be mediated by unactivated FXII signaling through the uPA receptor, stimulating processes such as endothelial cell growth and proliferation. This more recent finding highlights the variety of roles FXII has in human physiology, some of which might still need to be uncovered.

In conclusion, although clinical data on FXII does not support a pivotal role in haemostasis or thrombosis, new perspectives regarding the role of FXII have been discovered in the last two decades. These include a role in inflammation, fibrinolysis and angiogenesis, with novel pathways downstream of FXII still pending to be elucidated.

Potential areas for future investigation:

- **To establish w**hy gain of function mutations in FXII lead to an inflammatory, but not a thrombotic state
- To further delineate the relationship between structure and function of FXII

Figure 4

Potential physiological role of factor XII.

Abbreviations: HK, high-molecular-weight kininogen; FXII(a), (activated) coagulation

factor XII; PK, plasma prekallikrein; PKa, plasma kallikrein; BK, bradykinin; uPA,

urokinase plasminogen activator; tPA, tissue plasminogen activator; C3(a), (activated)

complement factor 3; C5(a), (activated) complement factor 5.

Biomechanics of fibrin and fibrin clot lysis

In both physiological and pathological conditions, thrombi are subjected to extreme mechanical forces such as wound stretch, clot contraction or shear stress. Yet, thrombi manage to retain their structural integrity through a remarkable combination of compliance and resilience. These characteristics are understood to be provided by the fibrin network, which forms the primary scaffold of clots. Fibrin networks can reversibly stretch up to ~150%, resist elongation of several hundred percent, and stiffen by at least two orders of magnitude before rupture (81,82). Biophysical studies over the past decade have shown that these unique mechanical features stem from the complex structure of fibrin fibers, which are bundles of protofibrils that are themselves double-stranded filaments of fibrin molecules. Consequently, fibrin networks undergo several phases of stretch at different structural levels (**Figure 5**) (83).

Insert figure

At first, stretch causes the natively disordered and hence flexible αC-domains of fibrin molecules to straighten, which allows elongation (i.e. strain) with almost no increase in resistance to deformation (i.e. elastic modulus). Next, the fibers gradually align in the direction of strain, which is accompanied by a strong increase of the elastic modulus. Finally, the strain is transferred to the folded domains of the fibrin monomers, which results in a further linear increase of the modulus. If the strain continues to be increased, however, the folded monomer domains start to unfold, which provides irreversible elongation, and eventually leads to rupture.

These insights into fibrin mechanics have only recently been acquired by applying novel methods based on rheology combined with in situ X-ray scattering or vibrational spectroscopy complemented with single-fiber and single-molecule stretching assays (82–84).

This mechanistic understanding of fibrin mechanics is ready to be used now to assess the role of mechanical forces in thrombotic and bleeding disorders. Thus far, clot characteristics have mainly been studied using microscopy. These studies found that patients with myocardial infarction, ischaemic stroke, venous thromboembolism, and recurrent episodes are characterized by *in vitro* fibrin clots with a dense network and thinner fibers (85). Such clots are known to be less permeable, making them less susceptible to fibrinolysis, which could explain associations to adverse outcomes. However, dense clots are also known to be stiffer, which potentially increases thrombus obstructiveness or embologenicity, giving an alternative explanation for differences in outcomes. In contrast, patients with hemophilia A and B were found to have clots with loose networks and thick fibers, which might make them more prone to bleeding events due to the fragility of such clots (86,87).

These findings suggest that mechanical phenotyping of clots is a promising avenue for future research. It might provide parameters that can contribute to more accurate diagnosis and risk stratification, mirroring the use of mechanical phenotyping for connective tissue disorders and cancer (88). Also, it could give rise to novel therapies using pharmacological or mechanical interventions that influence thrombus mechanics to, for example, improve outcomes of endogenous or therapeutic thrombolysis. However, much still needs to be elucidated about clot mechanics and the role of the fibrin network in physiology and pathology. Experiments on fibrin have mostly been performed in purified systems. This means it is largely unknown how fibrin interacts with other clot components such as platelets and red blood cells, and hence how thrombus composition and spatially heterogeneous structure affect thrombus pathologies (e.g. platelet- vs. fibrin-rich thrombi) (89,90). In summary, the integration of biophysical research into the field of thrombosis and hemostasis

is bound to bring fascinating fundamental insights and clinically relevant advances in the near future.

Potential areas for future investigation:

- The interplay of macromolecules including fibrin and different cell types (platelets, red blood cells) in clot mechanics and sensitivity to lysis.

- The relation between different mechanical properties of thrombi (stiffness, viscoelasticity, plasticity, rupture strength) and the risk of embolization and sensitivity of clots to lysis.

- Evaluate the potential of mechanical phenotyping of thrombi, either collected by thrombectomy or reconstituted from patient plasma, for diagnosis and risk stratification.

- Evaluate the potential of mechanical phenotyping of thrombi to assess the efficacy of novel therapies using pharmacological or mechanical interventions that influence thrombus mechanics to improve outcomes of endogenous or therapeutic thrombolysis.

Figure 5

*Elastic modulus of a fibrin network as a function of strain, measured by shear rheology.*

Fibrin forms a soft elastic network at low strain, and stiffens 100-fold in various stages

marked by the vertical dashed lines when the strain is increased. The stages correspond to

entropic elasticity (low strain), strain-induced fiber alignment, fiber backbone stretching,

and finally fibrin monomer unfolding.

The microbiome and thrombosis

In contrast to acute inflammatory conditions in case of viral infections, the gut microbiota is a driver of low-grade inflammation, chronically impacting vascular inflammation (91). Dependent on host nutrition, microbiota-derived products constantly leak into the portal circulation, with signaling-active molecules and metabolites reaching the hepatic microcirculation (92). Studies on germ-free mouse models clearly demonstrate that the transcriptome of the liver sinusoidal endothelium is broadly influenced by gut microbial colonization, with the sphingolipid synthesis pathway recently identified as one of the primarily affected microbiota-modulated pathways (93,94). Furthermore, von Willebrand factor (vWF) expression in the hepatic endothelium is augmented by the presence of gut commensals (95). Another example is the sensitivity of neutrophils towards lipopolysaccharide (LPS)-induced neutrophil extracellular traps (NET)osis, which was attenuated by the presence of gut commensals (96). Importantly, several experimental and clinical studies unveiled the gut microbiota as a novel risk factor for cardiovascular disease and arterial thrombosis (95,97–99). Interestingly, at low-cholesterol diet conditions, germ-free *Apoe*-deficient and germ-free *Ldlr*-deficient mice had elevated plasma cholesterol levels and *Apoe*-deficient mice presented increased atherosclerotic lesion size, an effect that was abolished at high-cholesterol diet feeding (100–102). Interestingly, in the germ-free Apoe-deficient mouse atherosclerosis model, *Roseburia intestinalis*, due to its production of the short chain fatty acid butyrate, has a protective role in atherogenesis (103). Another microbiota-derived metabolite related to cardiovascular risk and arterial thrombosis is trimethylamine (TMA), a choline-metabolite produced by TMA-lyase enzymes and converted to trimethylamine-N-oxide (TMAO) by flavin-dependent monooxygenase-3 in the liver (104–106). The metaorganismal TMAO-pathway was demonstrated to promote arterial

thrombus growth via multiple pathways, including the induction of platelet hyperreactivity and vascular endothelial TF expression (98,107). Of note, in a translational pig model it was recently demonstrated that the reduction of dietary fat for a time period of 30 days, resulting in reduced plasma cholesterol levels, was able to revert dysbiosis of the fecal microbiome and to reduce plasma TMAO levels, a predictive functional marker for adverse cardiac events. Vascular innate immune signaling, triggered by microbial-associated molecular patterns derived from the intestinal microbiota, for instance by the activation of endothelial Toll-like receptor-2 signaling in the liver resulting in enhanced vWF synthesis, is an additional mechanism linking the gut microbiota with enhanced arterial thrombus growth [5]. In contrast to germ-free mice, colonized mice showed increased ADP-induced GPIIb/IIIa activation and elevated adhesion-dependent phosphatidylserine exposure, promoting arterial thrombus growth (94,108). Intriguingly, gut microbial diversity might even affect cardiovascular disease therapies as shown for ticagrelor by a recent study on the efficacy of anti-platelet treatment in STEMI (113). Moreover, it was shown that chronic statin therapy is linked to lower prevalence of microbiota dysbiosis (109,110). In addition to above, abnormal gut microbiome homeostasis could be linked to development of chronic effects from viral infections (111). Alterations in gut microbiome have been reported, linked to cytokine release from cells, due to viral load, with implications also seen in SARS-CoV-2 infections (112,113). Also, circulating extracellular vesicles potentially transport viral miRNA in the gut, further promoting dysbiosis (114). Extracellular vesicles, carrying cytokines and pro-inflammatory markers may also further exacerbate atherosclerosis and viral infections, such as during COVID-19 (115,116).

Potential areas for future investigation:

- Based on gnotobiotic experimentation and insights from sequencing and multi-omics studies, it will be interesting to reveal microbiota-triggered molecular and cellular mechanisms involved in thrombogenesis at various settings.

- Given the broad interference of microbiota-derived metabolites with host metabolism and the microbiota-dependent regulation of host metabolic pathways involved in cardiovascular disease development, an improved understanding of their role in cardiovascular disease and thrombosis is needed.

- Well-designed functional studies are needed to identify microbiota-drug interactions, which, dependent on microbiome composition, can influence the outcome of antithrombotic therapies.

Viruses and coagulation: the case of COVID-19

Viral infections are associated with coagulation disorders, driven by inflammatory pathways (117,118). All aspects of the coagulation cascade, primary haemostasis, coagulation, and fibrinolysis, can be affected and the net result may be bleeding (119) and/or [athero]thrombosis (120). The spectrum of viral infections comprises different dynamics, ranging from acute to chronic and from a mild to a severe clinical course, resulting in a different interplay between the inflammatory and coagulation cascades and with different risk profiles for thrombo-embolic and/or bleeding complications. The interaction between infection, inflammation and the hemostatic system is a multifactorial dynamic process led by modifiable and non-modifiable risk factors. Unlike most bacterial infections treatable with specific antibiotics, no specific antiviral treatment is available for most viral infections, other than supportive treatment. Otherwise, the success of treatment interventions such as dexamethasone or anti-IL6, depends much on timing and it is a challenge to define the

optimal moment or time period of intervention in a heterogeneous patient population.

Investigation of coagulation disorders related to different viral infections has not been

performed uniformly, therefore common pathways are not fully elucidated yet. Furthermore,

research is hampered due to specific biosafety facilities needed to study specific viruses. A

better insight in pathogenesis on the one hand and improvement of bedside monitoring tools

on the other hand are urgently needed to improve clinical management.

An increasing body of evidence demonstrates extensive and bidirectional interactions

between inflammation and coagulation (117,121–126). Normally, coagulation is balanced by

pro- and (natural) anticoagulant mechanisms. Inflammation impacts the initiation,

propagation and inhibitory phases of blood coagulation (122). In viral and bacterial

infections, this can actually lead to both thrombotic and hemorrhagic complications.

Pathogens, as well as inflammatory cells and mediators, can induce the expression of TF on

monocytes and endothelial cell surfaces (126). Direct or indirect activation of the

endothelium by viruses or other pathogens may result in alterations in the coagulation and

fibrinolytic systems (127,128). There is also an incompletely understood connection of

infections with RNA viruses activating toll like receptor (TLR) 7 and autoimmune antibody

production (doi: 10.1126/science.abc0956). These antiphospholipid autoimmune antibodies

also develop in severe COVID-19 disease (doi: 10.1111/jth.15455).

The clinical picture of altered coagulation in several viral infections manifests itself in

bleeding (hemorrhage), thrombosis, or both. An exaggerated response may even lead to

disseminated intravascular coagulation (DIC) with the formation of microvascular thrombi in

various organs (129). DIC contributes to multiple organ failure and is associated with high

mortality in both bacterial and nonbacterial diseases (124,129)]. It is not yet clear why some

viruses cause haemorrhaging (e.g., Ebola), while others are associated with thrombosis (e.g.,

cytomegalovirus) and yet others show both complications (e.g., varicella zoster virus) (130–

132). Bleeding may be aggravated by the occurrence of thrombocytopenia either separately, or as part of viral coagulopathy (118). In addition to this, the bleeding complications of haemorrhagic viruses vary in severity, such as the minor bleeding complications in some forms of dengue and more severe bleeding in Ebola and Marburg. As mentioned for many viral infections, targeted therapy is not available, and only supportive care can be provided. In many mild cases, treatment may not even be necessary. However, to improve therapy and supportive care for complicated viral infections, a better understanding of the pathogenesis of bleeding and thrombotic complications due to viral infections is needed.

The case of COVID-19

In patients with severe COVID-19 infection many studies have shown that not the infection itself, but the host immune response results in a hyperinflammatory state , which can be a trigger of vascular thrombotic events, a phenomenon that we call immunothrombosis [pmid36466841]

The term thromboinflammation is derived from thrombosis associated with inflammation and is used to describe pathophysiologic perturbations due to vascular endothelial injury and/or loss of antithrombotic and antiinflammatory functions[Tanguay JF, Geoffroy P, Sirois MG, *et al.* Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1. *Thromb Haemost* 2004;**91**:1186-1193. doi: 10.1160/th03-11-0701]. Both cellular and humoral inflammatory mechanisms of immune surveillance are activated in this dynamic process. In acute infections, thromboinflammation may culminate in microvascular thrombosis, which is the hallmark of the disease, as has been reported in postmortem studies of patients with acute respiratory distress syndrome due to pathogens invading the respiratory tract and provoking an inflammatory response associated

with acute lung injury [Tomashefski JF, Jr., Davies P, Boggis C*, et al.* The pulmonary

vascular lesions of the adult respiratory distress syndrome. *Am J Pathol* 1983;**112**:112-126.

doi:]

Immunothrombosis, if balanced, is a physiological role in host defense. The term describes

the microvascular thrombotic response that facilitates microbe containment and elimination, a

critical component of innate immunity [Jackson SP, Darbousset R, Schoenwaelder SM.

Thromboinflammation: challenges of therapeutically targeting coagulation and other host

defense mechanisms. *Blood* 2019;**133**:906-918. doi: 10.1182/blood-2018-11-882993]

[Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. *Nat*

Rev Immunol 2013;**13**:34-45. doi: 10.1038/nri3345]. The pathological entity from

immunothrombosis is in situ pulmonary thrombosis which is a different entity from the

embolic events from deep vein thrombi which are a net result of thromboinflammation

[PMID36223804]. As part of any inflammatory response to attenuate microbial invasion,

microcirculatory thrombosis also produces multiorgan injury [Meyers S, Crescente M,

Verhamme P, Martinod K. Staphylococcus aureus and Neutrophil Extracellular Traps: The

Master Manipulator Meets Its Match in Immunothrombosis. *Arterioscler Thromb Vasc Biol*

2022;**42**:261-276. doi: 10.1161/atvbaha.121.316930] [Iba T, Levy JH. Inflammation and

thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in

thrombus formation during sepsis. *J Thromb Haemost* 2018;**16**:231-241. doi:

10.1111/jth.13911]. These important host defense mechanisms have been described, but with

the ongoing pandemic and massive numbers of COVID-19 patients who manifested lung or

multiorgan dysfunction, the concept of immunothrombosis was increasingly reported. doi:

10.1182/blood-2018-11-882993]. In summary, although thromboinflammation and

immunothrombosis have many similarities, they should not be used as interchangeable counterparts, even if they have been used synonymously in the past.

Long COVID defined as long lasting multiorgan symptoms that last for weeks to months after `SARS-CoV-2 infection, is associated with cardiovascular manifestations including peri-myocarditis. If and how in situ thrombosis does play a role in long COVID is still unanswered, studies are ongoing. Currently there is no guided therapy for long COVID other than anecdotal reports and further studies are needed to unravel the underlying mechanisms [PMID 35875883]

Potential areas for future investigation:

- Determine the viral or inflammatory triggers for either thrombosis and/or bleeding
- The role of vascular bed specific hemostasis in viral infections.
- Study the role of inflammatory components i.e. virus specific T-cells in the initiation and regulation of the hemostatic balance.
- Determine better ways of translating results from the homogeneous [experimental] models into clinical practice, or heterogeneous reality in order to improve the timing and type of therapeutic interventions.

Theme 3: How to limit bleeding risks: insights from translational studies

Genetics and bleeding disorders

Haemostasis is controlled by interplays between platelets, coagulation, and fibrinolysis; their normal function is to prevent bleeding. Genetic variants in genes that encode for regulators of these three processes are known to cause inherited forms of bleeding. The summary deals with the use of next generation sequencing (NGS) approaches for diagnostic and gene

discovery. To date, almost 100 curated disease-causing genes have been identified to cause inherited bleeding, platelet, or thrombotic disorders (www.isth.org/page/GinTh_GeneLists) (133). This is a dynamic list that is yearly updated as since 2011; 25 novel genes have been discovered using NGS approaches (134). This gene list is useful for clinical labs that have implemented multigene panel tests to diagnose inherited bleeding disorders. This is a cost-effective approach to rapidly screen patients. The international study ThromboGenomics has shown that the diagnostic rates obtained for thrombocytopenia, platelet function and coagulation disorders are 47.8%, 26.1%, and 63.6%, respectively, while this rate drops to 3.1% for patients with unexplained bleeding disorders (having normal laboratory test parameters) using a multigene panel test (135). These differences can be explained by the inclusion criteria and the quality of the laboratory test that detects the abnormality. Patients with abnormal test data for (anti-)coagulation parameters or with low platelet counts are easy to identify, and genetic variants are often associated with such defects. Still, genetic variants were also detected in some patients with normal laboratory parameters where these assays were unable to detect the defect. In contrast, the genes for the platelet function disorder 'storage pool disease' or having unexplained bleeding disorder are still unknown and therefore, screening with a multigene panel test is not useful as exemplified by causing a very low diagnostic rate in the Thrombogenomics study. Of interest, is the unexpected finding of oligogenic inheritance where patients have more variants in more than one gene. Today, this field still struggles with the detection of numerous variants of unknown significance (VUS) that can't be used in clinical practice (136). These VUS require further functional and genetic studies to prove pathogenicity. Rapid screening models and data exchange with the community could improve the variant classification.

International studies BRIDGE-BPD and NIHR BioResource have used WES and WGS for the discovery of novel genes for bleeding disorders (137,138). Success rates are typically high

if screening consanguineous or very large pedigrees, or if more families have been recruited with similar gene-phenotypes. Even if the genetic defect is discovered, it can take several years to understand the disease as illustrated for SRC-related thrombocytopenia (133). Five years after the discovery of the SRC gain of function variant E527K, the same variant was detected in other pedigrees that helped to delineate the syndromic phenotype associated with thrombocytopenia and RNAseq provided evidence for defective interferon regulation as underlying cause (133). Still many patients don't receive a diagnosis even though their complete genome has been analyzed. This can be explained by the fact that each genome contains numerous unique coding variants and the non-coding regions are very difficult to analyze due to the lack of information about regions of interest (promoter or regulatory regions) versus junk DNA. An additional layer of information will be critical to understand non-coding variation. Therefore, blood cell RNAseq will be performed for patients that don't have a diagnosis but from whom WGS data are available. Gene expression and splicing analysis will assist in the understanding of variants that influence these processes as the cause of a bleeding disorder.

Potential areas for future investigation:

- Oligogenic inheritance is unexplored in our field. It is currently not understood what the clinical relevance is of combining common and rare variants in different known genes that modify bleeding and thrombosis risks. This might be relevant for molecular diagnostics as it is known that single variants can result in a different clinical severity of a certain disorder.

- Some patients present with obvious clinical bleeding phenotypes but have normal laboratory test data. Genetic causes still remain unknown for such patients as it is very difficult to find causative genes if no idea of the underlying defective pathway is

known. It might be necessary to develop better laboratory assays to study such patients and these should include endothelial cells that are currently not studied.

- In addition to the currently used WES and WGS, other OMICS methods will be required to explore disease mechanisms and enhance gene discoveries. Novel statistical methods that can combine OMICS results will be required to address these needs.

Genetics and antithrombotics: towards individual drug tailoring

Personalized antithrombotic therapy based on genetic testing

Besides several other factors (i.e. body-weight, diabetes etc.) genetic polymorphisms play a role in the variable response of drugs in patients (139). Therefore, genetic testing may influence the efficacy and/or safety of antithrombotic treatment, and thus optimize patients' outcomes.

Genetic testing

When a nucleotide change in a gene is present in more than 1 percent of a population, it is called a genetic polymorphism. These polymorphisms often affect the drug-metabolizing cytochrome P450 (CYP450) enzymes, which play a role in activation or deactivation of a drug (140).

In patients with acute coronary syndromes (ACS) or undergoing PCI dual antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid) and a P2Y12-inhibitor (ticagrelor, prasugrel and clopidogrel) is the cornerstone of medical therapy to prevent the recurrence of thrombotic events including stent thrombosis (141). Ticagrelor and prasugrel are much stronger than

clopidogrel and have shown reduced thrombotic events in large outcome trials (142,143).

But, the reduced thrombotic risk is counterbalanced by an increased bleeding risk (142,143).

And it is well known that major bleeding has a similar impact on patient outcome as a

recurrent thrombotic event e.g myocardial infarction (144,145). Aspirin is metabolized by

different enzymes, but up to now none of the genetic polymorphisms has impacted clinical

outcome (146). Ticagrelor is a direct-acting drug, while both clopidogrel and prasugrel need

activation by cytochrome CYPP450 genes (147). The active compound of ticagrelor is

metabolized by CYP3A4, which can also directly bind to the P2Y12-receptor (148).

Prasugrel is metabolized mainly by CYP3A4 and CYP2B6, and to some extent by CYP2C9

and CYP2C19, however polymorphisms in these genes are not related with a heightened

thrombotic risk (149). However, clopidogrel is very much affected by polymorphisms which

lead to less response in 30% of patients (150).

In the two-step activation of clopidogrel process multiple CYP-enzymes play a role

(CYP2C19, CYP3A4/5, CYP1A2, CYP2B6, CYP2C9)(**Figure 6**) (151).

Henri hier figuur 6 plaatsen

CYP2C19 plays a role in both steps and is the greatest contributor in this metabolic process.

The prevalence of the CYP2C19 polymorphisms (*2 and *3) is ~25% of the Caucasian

population (147). There is much data demonstrating that carriers of CYP2C19 LoF-alleles

have a diminished antiplatelet response and therefore higher platelet reactivity (HPR) (152–

155). This HPR translates to higher risk for thrombotic events, including stent thrombosis

(152,156).

Figure 6

Biotransformation and metabolization of the oral P2Y12-inhibitors. Antithrombotic therapy can be personalized by (1) using CYP2C19 genotype guided therapy, which is the only genetic polymorphism for which a genotype guided therapy is assessed in randomized clinical trials or (2) assessing the actual responsiveness to antiplatelet therapy by measuring on-treatment platelet reactivity, which is influenced by different modifiable and non-modifiable factors.

Clinical evidence for a genotype guided antithrombotic therapy

Many studies have assessed a CYP2C19 genotype guided strategy (escalating or de-escalating) in patients with CAD (157,158). De-escalation means switching from a more potent drug (ticagrelor or prasugrel) to the less potent clopidogrel in extensive metabolizers, while escalation means switching from clopidogrel to ticagrelor or prasugrel in intermediate or poor metabolizers. De-escalation can be used in ACS, where standard treatment is ticagrelor. Escalation can be done in chronic coronary syndrome (CCS) patients undergoing percutaneous coronary intervention (PCI), stroke or peripheral artery disease, where clopidogrel is standard treatment.

In the randomized controlled trial (RCT), the Popular Genetics, a genotype-guided de-escalation strategy was tested versus usual care in 2,488 patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). All patients were treated with aspirin, but in the genotype-guided group, intermediate and poor metabolizers were treated with ticagrelor or prasugrel (39%), and extensive metabolizers with clopidogrel (61%). Patients in the control group were all treated with ticagrelor or prasugrel. Genotype guided P2Y12-inhibitor treatment reduced the bleeding risk (9.8 vs. 12.5%, HR 0.78, 95% CI 0.61 to 0.98, P = 0.04) and there was no increase in thrombotic events.

In the RCT, the TAILOR-PCI, 5,302 patients undergoing PCI for ACS or stable CAD were randomized to genotype-guided escalation or conventional therapy (clopidogrel) (159). In the genotype-guided group, intermediate or poor metabolizers were treated with ticagrelor (31%), and the other patients were treated with clopidogrel (68%). The primary analysis was only in patients who were intermediate or poor metabolizers and did not show a statistical difference in cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischaemia at 12 months (HR, 0.66, 95% CI 0.43-1.02; P = 0.06), but the reduced event rate suggests a clinical benefit with the genotype guided group. There was also no significant difference in bleeding between groups. Despite the fact that the trial was underpowered to

detect an effect size less than the pre-specified expected 50% relative risk reduction, it showed a promising reduction in thrombotic risk of genotype guided therapy. A meta-analysis including 15,949 patients with CAD showed that in intermediate or poor metabolizers ticagrelor/prasugrel reduced thrombotic risk as compared to clopidogrel, but in extensive metabolizers there was no difference in thrombotic risk whether patients were treated with ticagrelor/prasugrel or clopidogrel (157,158). Therefore, the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends to avoid clopidogrel in intermediate and poor metabolizers and use prasugrel or ticagrelor (157) (**Table 1**). Nevertheless, genotype guided antiplatelet therapy is not yet standard care in patients with CAD, although genotype guided de-escalation of P2Y12-inhibition has a class IIb Guideline recommendation and can be considered for ACS patients deemed unsuitable for potent platelet inhibition i.e. with a high bleeding risk (160).

Based on the above presented evidence some centers have implemented a genotype-guided strategy for P2Y12 inhibition (161). Their results are in line with previous meta-analyses and thus promising.

Most evidence for genotype-guided antiplatelet treatment was obtained in patients with CAD. Nevertheless, other vascular patients sharing the same pathophysiology may also benefit from genotyping. A meta-analysis in patients with ischaemic stroke or transient ischaemic attack (TIA), demonstrated that intermediate and poor metabolizers of clopidogrel have a higher risk of recurrent stroke (162). These results are supported by the RCT, the CHANCE-2, demonstrating in 6,412 patients with acute ischaemic stroke or TIA, who were intermediate or poor metabolizers of clopidogrel, that ticagrelor reduced thrombotic risk as compared to clopidogrel (163).

Table 1

Overview of the different CYP2C19 phenotypes with the coherent CYP2C19 diplotypes and the antiplatelet therapy recommendations when considering clopidogrel for cardiovascular indications.

Phenotype	CYP2C19 diplotypes	Response to clopidogrel	Therapeutic recommendation
Ultra-rapid metabolizer (UM)	*17/*17	Normal or increased antiplatelet response to clopidogrel	If considering clopidogrel, use at standard dose
Rapid metabolizer (RM)	*1/*17	Normal or increased antiplatelet response to clopidogrel	If considering clopidogrel, use at standard dose
Extensive metabolizer (EM)	*1/*1	Normal antiplatelet response to clopidogrel	If considering clopidogrel, use at standard dose
Intermediate metabolizer (IM)	*1/*2, *1/*3, *2/*17 or	Reduced antiplatelet response to	Avoid standard dose clopidogrel. Use prasugrel or ticagrelor at standard dose if no

	*3/*17	clopidogrel	contraindication
Poor metabolizer (PM)	*2/*2, *2/*3 or *3/*3	Significantly reduced antiplatelet response to clopidogrel	Avoid clopidogrel. Use prasugrel or ticagrelor at standard dose if no contraindication

Clinical rationale for antagonizing antithrombotic agents in bleeding patients

Novel reversal agents

Although the DOACs have considerably improved anticoagulant treatment, the risk of bleeding is still present. Importantly, all bleeds are multifactorial in nature depending on an interaction of modifiable and non-modifiable risk factors (PMID: 30376678 and 29510426). Furthermore, ethnic differences may play a role, as recently discussed for Asian populations and antithrombotic medication (PMID: 33171520). This implies that the presence of an anticoagulant, whether a VKA or a DOAC is merely a contributing factor, rather than a causal one.

Rapid reversal of the anticoagulant effect of DOACs may therefore be required in the case of life-threatening bleeding, emergency surgery, or severe trauma. Prothrombin complex concentrates and recombinant FVIIa have the ability to overcome the anticoagulant effects of DOACs. More recently, specific reversal agents have been developed that act as a decoy and scavenge the thrombin and FXa inhibitors. Idarucizumab is a monoclonal antibody fragment

that tightly binds to, and effectively counteracts the anticoagulant action of dabigatran (164).

For the FXa inhibitors, andexanet alfa was developed, a modified FXa molecule that lacks the

phospholipid-binding Gla domain, and has its active site mutated to prevent enzymatic

activity (165). Both idarucizumab and andexanet alfa have been registered, although not

everywhere in the world. Since both idarucizumab and andexanet alfa have to bind to their

target, they have to be in excess of the circulating anticoagulant and consequently large

quantities have to be administered, which is one of the reasons that their use is associated

with high costs. Also, these agents are specific for their target and knowledge about DOAC

intake has to be available before reversal can be initiated. The search for novel reversal

agents for anticoagulant drugs is therefore continuing.

Table 2 summarizes the available reversal agents and a number of novel reversal agents that

are currently under development. Scavenging proteins such as gamma-thrombin-S195A (for

dabigatran or potentially other anti-thrombin anticoagulants, (166) and Gla-domain less FXa-

alpha2-macroglobulin (for anti-FXa anticoagulants, (167) interact with the small molecule

anticoagulants and have been shown to be effective in vitro and in animal models.

Alternatively, several hemostasis enhancing proteins have been identified, characterized and

tested in vitro and in vivo. Examples for this approach are modified FX(a) molecules, such as

FXa-I16L, FX-C and FX-Phe174, and so-called superFVa.

FXa-I16L is a FXa molecule that is zymogen-like and therefore resistant to active site

inhibitors (168). Its activity is restored after binding to FVa and is thereby more potent than

decoy FX molecules. Because of its potent hemostatic enhancing effect, it not only

counteracts FXa inhibitors, but also thrombin inhibitors. This variant has been tested in a

phase 1 clinical trial, appeared safe and well tolerated (169), and demonstrated a dose-

dependent procoagulant effect.

FX-C is a chimera of human FX with an inserted 99 loop of snake FX from Pseudonaja textilis (170). This makes the molecule insensitive to FXa DOACs. Functionality has been proven in vitro and in vivo, and the molecule is currently undergoing phase 1 testing (source: VarmX website).

SuperFVa is an activated protein C resistant FVa variant with three mutations: Arg306/506/679Gln (171). In addition, a disulfide bond has been inserted between the A2 and A3 domains to enhance stability. SuperFVa improved thrombin generation in plasma and reversed bleeding by both FXa and thrombin inhibitors in mice (172).

Apart from protein approaches, there are currently two small-molecules in development as reversal agents. Ciraparantag, a small molecule that specifically binds to the DOACs and heparin, acts rapidly and reduces bleeding induced by these anticoagulants in animals (173). In humans, it is well tolerated (174). Major disadvantage of the (clinical) use of ciraparantag is that it can only be monitored with a whole blood clotting time, since it binds to citrate in collection tubes and to clotting reagents that are normally used in the coagulation laboratories.

Another small molecule under development is OKL-1111. This is a cyclodextrin that does not initiate coagulation, but enhances thrombin formation in both the absence and presence of anticoagulants. In bleeding models in animals, it could be demonstrated that reversal was obtained towards DOACs, low molecular weight heparin, vitamin K antagonists and clopidogrel (Meijers, unpublished observations) making it a truly universal reversal agent. Phase 1 studies are planned for 2023.

Potential areas for future investigation:

● Determine which of the characteristics of the novel reversal agents (specific or universal, small molecule or protein, decoy or non-decoy) will be leading in the choice for the best reversal agent.

● The next hurdle will be the demonstration of improved clinical outcome of novel reversal agents compared to prothrombin complex concentrate, idarucizumab or andexanet alfa in patients presenting with serious bleeding or requiring urgent intervention or surgery.

Table 2

Overview of reversal agents. The agents are categorized in reversal of dabigatran (anti-IIa), anti-Xa anticoagulants or with universal action. Furthermore, the agents were divided in proteins or small molecules and by mechanism of action (decoy or non-decoy). Yellow (protein-based, decoy), Orange (protein-based, non-decoy), Light green (small molecule, decoy), Dark green (small molecule, non-decoy).

Anti-IIa	Anti-Xa	Universal
Idarucizumab	Andexanet alfa	FVIIa
Gamma-thrombin-S195A	FXa-I16L	(a)PCC
	FX-C	SuperFVa
	FX-Phe174	Ciraparantag
	GladomainlessFXa-alpha2M	OKL-1111

Theme 4: Haemostasis in extracorporeal systems: the value and limitations of in vitro models

Assessing thrombosis and haemostasis ex vivo

Evaluation of the haemostatic process in pre-clinical as well as clinical settings becomes increasingly important in the assessment of the thrombotic or bleeding risk in patients. The routine haemostasis assays in the clinical diagnostic laboratory are imperative for the screening and diagnosis of haemostatic abnormalities and for monitoring the effectiveness of antithrombotic therapies, especially in high-risk patients. Although most widely used point-of-care assays like whole blood aggregometry and coagulation tests (PT, aPTT) can detect severe haemostatic defects and effects of pro- and antithrombotic drugs, these assays lack sensitivity and fail to measure the interdependency of haemostatic pathways, i.e. platelet activation, coagulation, fibrin formation and fibrinolysis, in clot formation (175–177)(**Table 3**). In an effort to include as many components of the haemostatic system as possible, more robust and global assays were developed such as thrombin generation assays, viscoelastic assays (thromboelastography/-metry) and microfluidic models (178); (175,179). Some of the global assays, like thrombin generation and thromboelastometry, have demonstrated potential to improve the identification of patients on antithrombotic drugs who are at risk of bleeding (180,181). Still, clinical applicability of these global assays is difficult due to (pre-)analytical variables, duration of test procedure and interpretation of test results.

Microfluidic flow devices have been used for decades mainly in research, enabling the simultaneous assessment of platelet and coagulation activation under flow conditions (182). In addition, endothelialized models allow to study effects of endothelial barrier function and endothelial activation on haemostatic processes, providing a more physiological approach to assess the risk of bleeding or thrombosis ex vivo (183,184). This has improved patient diagnostics and our understanding of inherited or acquired haemostatic abnormalities

tremendously. However, standardization of such assays and their (routine) use in clinical diagnostics remains challenging, in spite of previous efforts from international scientific committees and the general consensus on the need for standardization (185). Reasons for the lack of standardization include the complicated and time-consuming (pre) analytical handling of the (endothelialized) assays, alongside with high costs currently associated with available assays. Important aspects to enable translation of flow-based assays into clinical diagnostics or treatment monitoring include:

- the full automation in (pre)analytical handling

- easy-to-use software applications (development using artificial intelligence-based algorithms, integration of bioinformatics)

- fast, user-independent output

- cost-effectiveness

- manufacturability and implementation of quality control measures

- clinical validation of microfluidic assays

Multicenter studies - Committees

Applying global assays in multicenter studies will reveal the clinical value and applicability of (a combination of) these assays for risk prediction, diagnosis and treatment. These multicenter studies could accelerate the standardization of novel flow-based tests by providing access to large datasets and thereby allowing assessment of test variation between centers. In addition to achieving standardization at the level of manufacturing, sample preparation, data extraction and analysis, such studies can define patient populations that benefit from novel assays. In line with these goals, large multicenter studies come with swift recruitment of the appropriate patient population and adequate power. Thereby, setting of reference ranges can be established relatively easy for the general population and specific

disease states. When implementing global assays, evaluation of the net clinical benefit will be an important aspect to support the coverage of health care costs by health insurance companies. Moreover, funding for such efforts could be provided and/or supported by pharmaceutical companies, as the developed and tested global assays can also be used to test potential novel antithrombotic, pro-haemostatic drugs and antidotes in earlier phases. Approval processes of novel tests come with inherent challenges, but these can be tackled by involving expert committees that participate in clarifying and streamlining the process. Thereby, international scientific committees can initiate and oversee studies and publish results in standardized, internally validated ways (e.g SSC of ISTH) along with consensus statements so that petitioners for approval can follow a more efficient process.

Potential areas for future investigation:

- To further develop global haemostasis assays that encompass all aspects of haemostasis and to bring these from a research setting towards a clinical setting.
- To standardize global haemostasis assays and their corresponding analyses for the screening and diagnosis of haemostatic abnormalities.
- To define the optimal combinations of global and routine haemostasis tests for specific clinical questions or settings.

Table 3

Overview of hemostatic parameters and the corresponding clinical tests.

Haemostatic factor/process	Corresponding test
Platelet adhesion	Platelet function analyzer (PFA®)
Platelet secretion	Lumiaggregometry (ATP release) Flow cytometry (P-selectin)
Platelet aggregation	Aggregometry (e.g. Light Transmission Aggregometry, Multiple Electrode Impedance aggregometry) Platelet function analyzer (PFA®) Flow cytometry
Coagulation	PT, aPTT, thrombin generation Viscoelastic methods (e.g. ROTEM®, TEG®) Coagulation Factor determination
vWF	Platelet function analyzer (PFA®) Platelet agglutination assay vWF antigen and activity assay
Haematocrit	Haematology analyzer
Shear-dependent platelet function	Platelet function analyzer (PFA®)
Vasoconstriction	No test available, bleeding time is obsolete

Extracorporeal circuits and haemostatic challenges

Extracorporeal membrane oxygenation (ECMO) is a form of temporary life support for patients with severe but potentially reversible lung and/or heart failure, unresponsive to optimal conventional care. The ECMO machine provides blood oxygenation (veno-venous, V-V ECMO) or both oxygenation and circulatory support (veno-arterial, V-A ECMO) with an artificial circuit and membrane, thereby taking over the circulatory and respiratory functions (186). Thus, ECMO secures support while the healthcare team works on treating the underlying disease or until organs for transplant become available.

Although ECMO represents a potentially lifesaving therapy and its increase in clinical practice has mirrored a rapid expansion of research on this technology, it still retains intrinsic side effects and complications due to the artificial materials required and its effects on the circulatory, endothelial, haematologic, inflammatory, and immune systems.

Complications in patients receiving ECMO therapy are common and can be associated with worse outcomes (187). In particular, current rates of bleeding events are unacceptably high and reported to occur in approximately 30% of patients (188), with a 10% risk of major bleeding and 4–10% risk of intracranial hemorrhage (ICH) (189,190). Bleeding events independently impact patient prognosis, including mortality (191–193).

Patients undergoing ECMO support are predisposed to bleeding through various mechanisms, and these can be classified into patient, treatments, and circuit related. Many factors that may place patients undergoing ECMO at higher risk of bleeding have been identified (194), including underlying critical conditions prompting ECMO initiation, comorbidities, multiorgan dysfunction, and the technology itself (194–196). The contact between the patient's blood with the ECMO circuit and the systemic inflammatory response syndrome (SIRS) lead to activation of the coagulation cascade, with effects on fibrinolysis, thrombin formation, and platelet function (194,197,198). These changes to haemostatic balance result

in the coexistence of both thrombotic and haemorrhagic risks, and the final effects may be difficult to predict. Moreover, although anticoagulation remains a standard practice in patients undergoing ECMO (199,200), thrombotic events have been identified in approximately 15 % of ECMO courses (201) and might complicate ECMO therapy with significant morbidity and mortality.

Despite the increasing clinical experience and research data available, much is still unknown about best practices and risk minimization in patients receiving ECMO therapy. In addition, our current knowledge and understanding of what predisposes patients on extracorporeal circuits to bleeding or thrombosis are poor. Therefore, advancement in prevention and early recognition of haemostatic complications, both haemorrhage and thrombosis, is essential to improve the management and outcomes of patients undergoing ECMO. A genetic predisposition to coagulation disorders in these settings, where blood and body are exposed to artificial surfaces, is already well-known but still poorly investigated and might represent an additional target for future research.

Unfortunately, there is a lack of consensus regarding the most suitable approach to best identify risk factors, especially in very sick patients, and genetic screening, whilst attractive, may not be proven fruitful.

Truth be told, since both ECMO patients and ECMO technology imply the involvement of multiple variables and biological pathways, our current clinical practice may suffer from a compartmentalized approach. Therefore, cooperation between basic scientists and clinicians is very much needed to bridge the gap, tackle the challenges, and reply to the compelling questions that are still waiting to be answered. While historically, the well-known strategy "divide et impera" has been used by empires to succeed in expanding their territories, the scientific community should come together and share our knowledge and resources to thrive.

Potential areas for future investigation:

- Current rates of bleeding in patients treated on extracorporeal circuits are unacceptably high.

- Our current knowledge and understanding of what predisposes patients on extracorporeal circuits to bleeding or thrombosis are poor.

- Cooperation between basic scientists and clinicians is needed to bridge the gap to enable the difficult questions that need to be answered regarding the use of extracorporeal circuits.

- Lack of consensus on prioritizing those studies that would best identify risk factors, especially in patients who are very sick and with multiple biological pathways involved.

- Genetic screening, whilst attractive, may not be proven fruitful.

Generating novel vascularised organoids for disease modeling and drug development

The advent of organoids, bioprinting, and organ-on-a-chip technologies has at long last offered viable alternatives to simplistic in vitro models and non-human in vivo approaches (202–204). Species and tissue specific 3D cultures which mimic the architectural, molecular, and cellular complexity of human organs (to varying degrees) offer many of the benefits of in vitro systems (scalability, manipulability etc.). They have demonstrated remarkable utility in drug screening, the generation of patient-specific and precision medicine models, and are allowing for unique insights into how cells interact with one another in complex 3D structures (202).

During the SARS-CoV-2 pandemic, organoid models demonstrated their utility in investigating poorly understood aspects of disease pathology. Our own work using microvascular organoid models demonstrated an important role of pericyte mediated viral uptake in the loss of vascular integrity contributing to thrombosis in severe COVID-19 infection (205). More recently, a vascularised bone marrow organoid was developed and validated which faithfully recapitulates key features of the myelopoietic central bone marrow. It was demonstrated that this system allows for drug screening in the context of myelofibrosis, but more importantly supports the engraftment of primary patient cells from a number of cancers which have been classically difficult to study ex vivo (primary myelofibrosis, multiple myeloma, acute lymphocytic leukemia) (206).

With the promise of these approaches in mind, they are not without their limitations. Self-arranging organoids, particularly those derived from human induced pluripotent stem cells (hiPSCs), remain relatively fetal in their development, and engineering more 'adult' versions of these systems remains a key area of study and improvement. While 'organ-on-a-chip' and bioprinting strategies offer the promise of mimicking more adult tissue, they do so at the cost of the scalability and accessibility of these models. Moreover, cost remains a significant factor in the generation of certain organoid systems.

As the tissue engineering field continues to grow and expand, a key consideration is interpreting data derived from these models. While most researchers would balk at the notion of completely replacing animal systems with 3D human models, this is ultimately the end goal of many who are working in the field.

Key questions remain: how to reconcile conflicting human and murine data? How to meaningfully interpret mechanistic information in a (still) artificial system? These and other considerations are, and should be, part of the on-going dialogue between basic scientists, engineers, and clinicians about meaningfully exploiting what promise to be revolutionary approaches to how to model disease and develop therapies.

Potential areas for future investigation:

- Organoids are an important advance that will enrich the drug discovery process, alongside the use of current assays/mouse models.

- Organoids could be used as part of an iterative approach, with simpler organoid models used in screening before moving on to more complex systems.

- Use of organoids to instruct choice of drug in personalized medicine approaches is challenging and currently unproven, but with future developments could be feasible and valuable.

Figure

Balancing system complexity with throughput to meaningfully address biological and translational questions. With the development of progressively more physiologically relevant and complex *in vitro* models, there is a concurrent decrease in throughput which has significant implications for addressing biological questions. A key consideration will be maintaining scalability, both experimentally and in terms of cost, as improved 3D cultures, microfluidic platforms, and bioprinted models are developed.

Theme 5: Clinical dilemmas in thrombosis and antithrombotic management

New insights into inherited thrombophilia

The association between inherited thrombophilia and the occurrence of (recurrent) venous thromboembolism (VTE) has been demonstrated in the past focusing only on a few genetic defects including antithrombin (AT), protein C, protein S deficiencies and two

polymorphisms, factor V Leiden (FVL) and prothrombin G20210A mutations (207). Surprisingly, the vast majority of information clinicians daily use for the management of thrombophilic patients is based on the results of previous studies only dealing with thrombophilia mechanisms discovered in the second half of the last Century. In contrast, it is commonly seen that in a large number (almost 50%) of families symptomatic for thrombophilia, none of these defects can be identified. The logical consequence is that other still unknown inherited thrombophilia may exist. Recently, new genetic defects responsible for severe thrombophilia have been identified, namely, pseudo-homozygosity for activated protein C (APC) resistance, the hyperfunctional factor IX and FVIII, and the resistance to AT (207).

FVL is responsible for about 95% of cases of APC resistance. However, several point mutations in the F5 gene causing APC resistance have been identified in different populations (207). Recently, severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon) has been described that affect anticoagulant pathways more strongly than the prothrombinase activity of FVa (208). It can also occur that heterozygous FVL carriers present with a concomitant heterozygous F5 gene mutation responsible for FV deficiency, resulting in the 50% of FV plasma levels being all FVL. In these pseudo-homozygotes the thrombotic risk is as high as that observed in homozygous individuals (209).

Factor IX Padua is a gain-of-function mutation in the F9 gene (R338L) discovered in 2009 detected in a family symptomatic for VTE and exhibiting extremely high plasma factor IX activity (eight times the normal) with concomitant normal antigen levels (210). Very recently, another hyper-functional FIX variant (R338Q, Factor IX Shanghai) was identified in a 13-year old boy referred for recurrent deep vein thrombosis (211). In 2021 the first thrombophilic defect in the F8 gene (FVIII Padua) associated with markedly elevated FVIII

levels and severe thrombophilia was described in 2 Italian families (212). Genetic analysis revealed a 23.4-kb tandem duplication of the proximal portion of the F8 gene (promoter, exon 1, and a large part of intron 1), which co-segregated with high FVIII levels in the family. Finally, in 2012 a novel gain-of-function polymorphisms leading to resistance to AT have been identified (213). The molecular basis is a missense mutation of the prothrombin Arg596 residue (exon 14) resulting in impaired thrombin–AT binding and defective inhibition of the mutated thrombin by AT. Other similar cases were subsequently described in Serbia, India and Italy. The symptomatic five families show three different mutations of the Arg596, and namely: prothrombin Yukuhashi Arg596Leu (213), prothrombin Belgrade and Amrita Arg596Gln (214,215) and prothrombin Padua 2 Arg596Trp (216). Although all these hereditary thrombophilias are rare, clinicians ought to keep in mind these novel mutations when dealing with patients or families with unexplained history of recurrent VTE. Nonetheless, the large number of newly discovered inherited defects in the last decades seems to justify why one should not abandon testing for thrombophilia patients belonging to families with VTE.

In fact, previous epidemiological studies and recommendations are based on limited knowledge of inherited thrombophilic conditions. Advanced diagnostic tools including next generation sequencing (NGS) are now adding important information on the etiology of thrombosis. Thus, new clinical studies are needed to re-define the role of inherited thrombophilia in the management of patients with thrombosis.

Managing atrial fibrillation in haemophilia

In the community of patients with haemophilia (PWH), cardiovascular disease is an emerging medical issue as the lifespan of these individuals continues to approach that of the general population (217). A specific topic concerns patients with atrial fibrillation (AF), where anticoagulants are widely used for the prevention of ischemic stroke and systemic embolism. The overall prevalence of AF in PWH in Europe is 0.84% and increases to 3.4% in patients >60 years and is therefore not different from that in the general population(218). In a patient with a congenital bleeding disorder such as haemophilia, the decision to start antithrombotic therapy is even more challenging as the balance between thrombosis and haemorrhage is quite delicate.

In PWH with AF, there are many uncertainties to deal with by clinicians in clinical-decision making. First, the minimum clotting level to be able to start anticoagulation therapy is unknown. Several experts and consensus statements suggest that a minimum factor VIII/IX level of 20-30 IU/dL is needed for oral anticoagulation (217–221) and this is somewhat confirmed by a clinical registry (222). On the other hand, PWH with factor levels <20 IU/dL might be considered naturally anticoagulated, as depicted by lower endogenous thrombin potential levels (223).

In the general population with AF a risk score, such as the CHA_2DS_2-VASc score score, is used to identify patients at risk for ischemic stroke and therefore in need for anticoagulation therapy. In addition, the HAS-BLED score has been used to predict bleeding events on oral anticoagulation therapy. Balancing these 2 scores helps the clinician to decide whether the downside of oral anticoagulation outweighs the prevention of thrombotic events. However, in PWH these scores have not been and probably never will be prospectively validated due to the low number of adverse events in this specific population. Therefore, due to lack of evidence, treatment of PWH with AF should always be individualized taking into account the

bleeding and thrombotic risk. As a general thought, PWH with factor levels <20 IU/dL probably do not need additional antithrombotic therapy. In patients with mild haemophilia (>20 IU/dL), oral anticoagulation therapy is probably feasible. In that case, a direct oral anticoagulant (DOAC) has the preference over vitamin K antagonists due to their favorable safety profile (224).

There is a strong need for more clinical data on anticoagulation therapy in PWH. Ideally, a registry is started to document the efficacy and safety of different types of antithrombotic treatment in PWH. However, due to the low event rates this will be a difficult task. Furthermore, there is a need for clinical validation of global haemostatic assays or thrombin generation tests to adapt individualized treatments. Especially, with the rapid adaptation of non-factor replacement therapies (i.e. emicizumab), our long lasting experience with factor levels will be challenged and the need for these haemostatic tests will be increasing.

The elusive safe antiplatelet agent

Platelets are activated by two major groups of receptors, G protein-coupled receptors (GPCR) which are the targets for current antiplatelet drugs, and tyrosine kinase-linked receptors which are targets for a new class of antiplatelet agent. All of the current antiplatelet drugs increase the risk of bleeding and this can give rise to nuisance bleeds that may influence compliance and, in a minority of patients, life-threatening bleeds. Furthermore, over 50% of patients on antiplatelet medication experience further thrombotic episodes. Thus, there is an urgent need for drugs with improved efficacy that spare haemostasis.

The last major, widely prescribed new class of antiplatelet drug introduced into the clinic was that of the $P2Y_{12}$ receptor antagonists over 20 years ago, with the thienopyridine, clopidogrel,

being the first in class. Several other P2Y$_{12}$ receptor antagonists have since been introduced of which ticagrelor is the most notable because of its reversible action and greater efficacy. This offers an advantage over the irreversible thienopyridines but at the risk of increased bleeding. A PAR1 thrombin receptor antagonist, vorapaxar, has also been introduced but has not been widely described due to the increase in risk of bleeding.

The major tyrosine kinase-linked receptors in terms of signal strength are those with a motif in their cytosolic tail known as an immunoreceptor tyrosine-based activation motif (ITAM). Human platelets express three ITAM receptors, CLEC-2, GPVI and FcγRIIA, and all three signal through Src, Syk and Btk tyrosine kinases. However, within this group, only the collagen and fibrin(ogen) receptor GPVI has been shown to play a role in haemostasis, although the importance of this appears to have been overestimated. This is shown by clinical data on patients in Chile with an insertion mutation that introduces a stop codon prior to the transmembrane sequence of GPVI and thus prevents surface expression. It is estimated that over 4,000 individuals are homozygous for loss of GPVI in Chile and yet only 12 cases from 11 unrelated families have been found (225). The majority of these have a mild bleeding diathesis which in some cases has diminished/disappeared on reaching adulthood. Furthermore, only two patients with an inherited deficiency in GPVI have been reported outside of Chile. Given that collagen is a standard agonist in the clinic for the study of patients with a suspected platelet disorder, these data suggest that loss of GPVI does not give rise to a major bleeding diathesis.

This conclusion is also supported by a Phase I safety trial on a GPVI-blocking Fab, now known as glenzocimab (226). A press release In February 2022 on a Phase Ib and IIa trial on glenzocimab reported a tendency to a reduction in bleeding and improvement in cognitive

symptoms in patients with acute ischaemic stroke when given in combination with standard treatment (thrombolysis or thrombectomy). This study was powered for safety rather than efficacy but the observation of an encouraging therapeutic effect provides a basis for a phase III trial and reinforces GPVI as a target for a new class of antiplatelet drug.

This safe targeting of GPVI in terms of bleeding is further supported by clinical data on the use of Btk and Syk kinase inhibitors in the treatment of B cell malignancies and immune thrombocytopenia (ITP). In both cases, the bleeding symptoms reduce over time showing that ITAM-based signalling pathways can be safely targeted (in terms of bleeding) with kinase inhibitors even when the starting platelet count is thrombocytopenic. Inhibitors of Src, Syk and Btk tyrosine kinases have been introduced into the clinic for treatment of these disorders and have been shown to be well tolerated for up to several years. Moreover, these inhibitors target activation of platelets by all their ITAM receptors. The first generation inhibitor of the Tec family kinase Btk, ibrutinib, was been shown to cause excessive bleeding raising concerns about its use as an antiplatelet drug, but this is now recognized to be due to one or more off-target effects, most likely on other kinases. The second and third generation inhibitors of Btk, such as acalabrutinib, and the Syk inhibitor, fostamatinib, have been shown to be well tolerated in patients, with bleeding symptoms reducing over time as patients respond to treatment. This is particularly notable for fostamatinib which is used in patients with refractory ITP and who therefore have a low platelet count (227).

The C-type lectin-like receptor CLEC-2 appears to have little or no role in haemostasis in human and an uncertain role in arterial thrombosis. In contrast, CLEC-2 has been shown to drive thrombosis at sites of inflammation in the venous system in mouse thrombo-inflammatory models, namely deep vein thrombosis (DVT) and bacterial infection (228).

Platelet activation in these models is mediated by inflammation-driven up-regulation of the ligand for CLEC-2 in the vessel wall podoplanin. Patients treated with ibrutinib show a reduction in DVT suggesting that CLEC-2 may also drive thrombosis in thrombo-inflammatory disease in humans (229).

The low affinity immune receptor FcγRIIA is the only Fc receptor on platelets and has no known role in haemostasis. Activation of FcγRIIA underlies heparin-induced thrombocytopenia (HIT) which is associated with a marked reduction in platelet count and in some patients life-threatening thrombosis. The molecular basis of this disorder is the formation of antibodies that bind to the positively charged chemokine PF4 which forms an immune complex with the negatively charged heparin. A related, but much rarer condition, with less than 50 cases world-wide, autoimmune HIT, is also mediated by anti-PF4 antibodies but is independent of heparin. In February 2021, the first cases of a new syndrome, now known as vaccine-induced immune thrombocytopenia and thrombosis (VITT), were identified in patients who had received a first dose of the Oxford-AZ adenovirus vaccine to Sars-Cov-2 in the previous 5 – 20 days. The frequency of VITT is extremely low, in the order of 1:50,000 – 100,000. VITT is also mediated by antibodies to PF4, with the binding of PF4 to the adenovirus vector driving antibody production (230). Platelet activation by sera from patients with VITT can be prevented by treatment with a Src, Syk or Btk inhibitors although the low frequency of the syndrome, cost of the kinase inhibitors, and potential side-effects prevents this being translated to a clinical trial (231).

In summary, platelet tyrosine kinase-linked receptors, notably GPVI, represent targets for a new class of antiplatelet drug that may be more powerful against arterial thrombotic disorders such as acute coronary syndromes and ischaemic stroke than current drugs with a reduce risk

of bleeding. In addition, they are targets in both thrombo-inflammatory disorders and immune complex-driven thrombosis, two groups which are not currently treated with antiplatelets. Receptor blockade can be achieved using protein-based inhibitors such as the GPVI Fab glenzocimab or small molecule inhibitors targeted to Src, Syk or Btk tyrosine kinases. Potent small molecule inhibitors of GPVI, CLEC-2 and FcγRIIA have not been identified. The kinase inhibitors have the advantage of being orally available and blocking activation by all three ITAM receptors but with the concern of off-target effects on myeloid cells and lymphocytes leading to an increase in susceptibility to infection. The irreversible nature of the second and third generation Tec family kinase inhibitors such as rilzabrutinib may enable them to be used at a much lower concentration thus reducing off-target effects (232).

Will FXIa inhibition fulfill a promise?

FXI deficiency (hemophilia C or Rosenthal disease)

In 1953 Rosenthal et al described this autosomal disorder in a family with bleeding events during surgery or dental procedures. The prevalence of severe FXI deficiency is about ≈ 1/Million, and more frequent in certain populations. Clinically, the prolongation of the APTT may lead to the diagnosis, rather than bleeding complications, which are generally mild, even in severe deficiency. Bleeding may be provoked by surgery, particularly in tissues with high fibrinolytic activity like urogenital or oropharyngeal, but may also include epistaxis, heavy menstrual bleeding or post injury, while unprovoked bleeding into muscle or soft tissue or haemarthrosis are not frequent.

Bleeding may also occur in heterozygous subjects with mild deficiency /20%-60%) and does not correlate with FXI level. Bleeding can be corrected by FXI (blood product or recombinant clotting factor). Pronounced FXI deficiency lowers risk for ischemic stroke and venous thrombosis.

FXI (a) inhibition

FXI(a) is therefore an interesting target for antithrombotic therapy as upstream inhibition of the intrinsic cascade may be effective, yet potentially safer with regards to bleeding as FXI-deficient patients rarely have spontaneous bleeding, suggesting that FXI may have a limited role in haemostasis. $FXI^{-/-}$ mice have normal tail bleeding times but show decreased clot formation at injury sites of arterial or venous (233). Likewise, treatment of rodent or rabbit models with FXI antisense oligonucleotides (FXI-ASO) or anti-FXI antibodies has shown resistance to experimentally induced thrombosis and a low risk of bleeding complications (234), (235). Different strategies targeting FXI/FXIa for antithrombotic therapy are under development in clinical trials. Novel FXI inhibitor agents include inhibitors of biosynthesis, antibodies and small molecules (**Table 4**).

Table 4

Factor XI(a) inhibition.

	Type of FXI inhibition	Administration	frequency	Onset of action	Offset of action	Renal excretio

								n
ASOs	Block biosynthesis	Parenteral		Weekly to monthly	Slow	(weeks)	Slow (weeks)	No
Antibodies	Bind target protein	Parenteral		Monthly	Rapid	(hours to days)	Slow (weeks)	No
Small molecules	Bind target protein	Oral	(or parenteral)	Daily	Rapid	(minutes to hours)	Fast	Yes
Natural inhibitors	Bind target protein	Parenteral		Daily	Rapid (minutes)		Fast	Uncertain
Aptamers	Bind target protein	Parenteral		Daily	Rapid	(minutes to hours)	Fast	No

The clinical trials of targeting FXI

Four FXI(a) inhibitors have been tested in patients undergoing total knee arthroplasty (TKA). FXI ASO IONIS-FXIRX that inhibits FXI biosynthesis in liver and Abelacimab (MAA868) that inhibits FXI by binding the catalytic domain of both FXI (zymogen) and FXIa were compared to enoxaparin (40mg) for prevention of VTE in TKA patients. In the FXI ASO trial , the study showed that the higher dose (300mg) regimen (4%) was superior to enoxaparin (30%) for the prevention of VTE and had lower rate of bleeding events than with enoxaparin (236). Similar as the FXI ASO result, the trial of Abelacimab showed that the incidence of

VTE in 30mg abelacimab regimen was noninferior to enoxaparin, and the 75mg and 150mg abelacimab regimens were superior to enoxaparin (P<0.001) (237).

Osocimab (BAY 1213790), a monoclonal antibody that can inhibit FXIa was tested in 813 adult TKA patients (FOXTROT,). Osocimab (0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/kg) was compared with enoxaparin and apixaban for thromboprophylaxis, and non-inferior with respect to efficacy, while it caused less bleeding (238). Likewise, milvexian, a small molecule that inhibits FXIa activity, was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding when compared to enoxaparin at five different dosing regimens . Hence, these trials demonstrated that FXI contributes to postoperative VTE and that lowering FXI levels or inhibiting its activity, provide an effective and possibly safe method for its prevention.

For the patient with AF, Abelacimab (120mg, 180mg) (NCT04213807) and the small molecule asundexian (BAY 2433334) (PACIFIC-AF, NCT04218266) are compared with placebo or apixaban. The first Phase 2b trial data of PACIFIC-AF were already published. Compared with apixaban in patients with AF at risk of stroke, the bleeding rate for the primary endpoint (ISTH major and clinically relevant non-major bleeding) was reduced by 67% in patients receiving Asundexian (46,239). However, PACIFIC-AF was not powered to test differences in rates of thrombotic events between groups. There are another 2 different phase II clinical trials in which asundexian was tested: PACIFIC AMI and PACIFIC Stroke . that were both recently published.In patients with acute coronary syndrome (NSTEMI and STEMI), asundexian on top of dual antiplatelet therapy (ASS plus any P2Y12 inhibitor)resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events when compared to DAPT alone (240). In patients with non-cardioembolic ischemic stroke, asundexian on top of single

antiplatelet therapy did not increase the risk of major bleeding, but did also not reduce the composite of covert brain infarction or ischaemic stroke (241). In the Axiomatic trial, the safety of milvexian, another direct FXIa inhibitor, was tested in non-cardioembolic stroke compared to placebo. Similarly, this trial did not show significantly increased bleeding compared to placebo, without having the power to assess efficacy. Taken together, these findings warrant further investigation in phase III clinical trials. The OCEANIC AF (NCT02168829) is the first of this kind to test efficacy of asundexian as compared to apixaban in atrial fibrillation.

Bleeding management of FXI deficiency and of FXI inhibition

For the clinical use of factor XI inhibitors - not only those with the long half life - the management of bleeding or peri-procedural management is crucial. Bleeding management in patients with factor XI deficiency includes Fresh frozen plasma, FXI concentrates (half-life 50 to 70 h), which may be administered every 48 to 72 hours, also low-dose recombinant factor VIIa [e,g, lower doses of rFVIIa (15-20 µg/kg)], and antifibrinolytic agents, such as tranexamic acid. Antithrombotic agents, such as anticoagulants and antiplatelet medications, should generally be avoided.

Reversal studies of factor XI inhibitors are being performed in healthy volunteers using PCC and rFVIIa, and fully human antibody Fab with very high affinity for FXIa inhibitors are being explored for their potential to neutralize their anticoagulant effects.

Outlook for FXI inhibition

The pathophysiologic concept of factor XI inhibition with separating thrombosis from bleeding is very promising and supported by the clinical presentation of FXI deficiency

patients and animal models. In addition, factor XI inhibition also links to inflammatory pathways and with the contact pathway may also be an effective antithrombotic treatment for foreign surfaces.

However, the benchmark of today´s anticoagulant treatment achieved with DOACs is not easily surpassed. Therefore, identifying the important medical needs, selecting the appropriate indications and choosing the optimal trial design will determine the future success of factor XI inhibition. Potential other areas of interest are patients with cancer and thrombosis and patients with severe renal insufficiency or other factors that are associated with high risks for bleeding (and thrombosis).

How to prevent thrombosis in the next corona pandemic; lessons learned

COVID-19 brought the clinical and research world into widespread recognition of the problem of coagulopathy in infections. Very early identification of thrombosis in patients with COVID-19 first reported from China paved the way for the publication of a flurry of guidelines focused on the antithrombotic management of these patients (242). Soon after, the research world started turning their attention to the mechanisms of thrombosis in COVID-19 and how the different pathways may be involved in the thrombotic complication (243). In the Maastricht discussion, several clinical pointers were presented to assist in future management of haemostatic and thrombotic complications associated with infections. In COVID-19, the preponderance of thrombosis is in the pulmonary circulation (244). This should ideally be termed as pulmonary thrombosis rather than pulmonary emboli. The rationale for this consideration is the activation of localized bronchoalveolar coagulation by the SARS-CoV-2 virus and the hosts' immune system (widely known as immunothrombosis) in the causation of these clots. These are different to the emboli from lower limbs or other parts of the

circulatory beds which is commonly recognised as pulmonary emboli. The presence of localized coagulation systems may occur in the gastrointestinal tract and possibly the integumental barrier or at sites where pathogen entry is likely. Moving on to the laboratory aspects, D-dimer elevation is a characteristic aspect of COVID-19 (245). This is predominantly due to alveolar fibrinolysis rather than clot breakdown and hence correlated with prognosis in these patients rather than with thrombotic risks. A useful future study would be to look at how extravascular fibrinolysis may correlate with disease outcomes in different pathological states. Severe thrombocytopenia is rare in COVID-19 although mild to moderate drop in platelet counts can be common (246). There are also reports of markedly elevated VWFlevels in these patients too, which in some reports were correlating strongly with poor outcomes. Can these two be linked? Possibly, the thrombocytopenia is caused by the release of large amounts of VWF from endothelial activation which means a decrease of platelet counts can be suggestive of microthrombi formation. This leads to under-recognition of microvascular thrombi from a clinical point of view. In the absence of other clear explanations, a drop in the platelet counts or fibrinogen levels in the setting of sepsis or inflammatory states may mean formation of microthrombi and the need for intervention to limit this process. But the timing of intervention is important too. Coagulation systems including platelets and fibrinogen are anti-infective and as such are commonly activated in different infections. There is a fine line between this beneficial effect of the host's haemostatic system turning to the harmful state of micro- and macrovascular thrombosis. The ideal time for intervention is that period when the shift to harm from a beneficial period occurs (247). Monitoring trends in the common tests may be the way forward in this regard but future research should also focus on the different pathways and the correct timing for intervention targeting the coagulation system in infections.

Ticardio translational lecture: Ambivalent role of leukocyte-derived microvesicles in hemostasis

Microvesicles, resulting from vascular and blood cell activation, are now recognised as new protagonists in cellular crosstalk involved in thrombo-inflammation.

Initially described as catalytic surfaces able to activate TF-dependent procoagulant pathways, Leukocyte-derived Microvesicles (LMV) were more recently ascribed a fibrinolytic activity (248,249). Using first whole blood stimulated with LPS (LPS-MV) to mimic inflammatory conditions, granulocytes MV were found to lyse a thrombus in vitro, according to their Plasmin Generation Capacity (MV -PGC), in a uPA/uPAR dependent manner (250). Second, defining MV coagulolytic balance (MV-CLB) as the ratio between MV procoagulant and fibrinolytic activity, the impact of MV- with distinct CLB profile was investigated on the dynamics of thrombus formation in vivo, using laser injury model of mice arterial thrombosis and intravital microscopy. Interestingly, plasminogen accumulation reflecting fibrinolysis initiation was higher in mice receiving fibrinolytic EV-BCL compared to procoagulant EV-CLB profile.

Accumulated knowledge on the role of LMV has not only revisited their role as ambivalent catalytic surfaces able to tune a coagulolytic balance (251–253) but have also driven technological advances, resulting in the development of sensitive and specific assays allowing to measure MV driven TF procoagulant and plasmin fibrinolytic activity (254–256). According to TICARDIO objectives on new pathways and targets involving LMV in immuno-thrombotic responses and their translation into novel diagnostic and therapeutic strategies, sepsis induced coagulopathy was chosen as a typical thrombo-inflammatory clinical situation associating coagulation activation and abnormal fibrinolysis. While converging animal and clinical studies emphasized the deleterious role of procoagulant MV

in sepsis and septic shock, the hypothesis was that MV have a protective effect supported by their capacity to lyse a thrombus. Granulocyte MV from sepsis patients were found to display a heterogeneous pattern of PGC, driven by uPA-uPAR expression and were able to lyse a thrombus according to their MV-PGC level. Injection of granulocyte MV with high PGC level reduced clot formation and improved survival in a mice model of septic shock, demonstrating a protective effect of these granulocytic subpopulations (250), opening perspectives for potential antithrombotic strategy. In a cohort of 225 patients with septic shock enrolled in a multi-center prospective study, the MV-CLB predicted mortality in septic shock patients with better performances than the procoagulant and profibrinolytic activities taken individually, and allow to stratify the severity of septic shock . This new functional signature of MV opens unexplored avenues for the guidance of individualized therapy targeting coagulopathy in septic shock.

Data presented in the SEPSIS context illustrate the view of Granulocyte MV CLB as an ambivalent microsystem tuning thrombo-inflammation.

Potential areas for future investigation:

- from one side , a deeper understanding of what determines the MV BLC , including the role of the distinct triggers and subsets of MV and the impact of pharmacological modulations,

- from another side, the definition of the true value of MV as biomarkers of thrombotic risk , through multicentre prospective clinical studies thank to methodological innovation and standardization, to measure MV in a more automatized way and integrate them into scoring systems with other biomarkers and clinical variables. These perspectives are included in ongoing research programs (115).

References

1. Owolabi MO, Thrift AG, Mahal A, et al. Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health 2022; 7: e74–85.

2. Kamarova M, Baig S, Patel H, et al. Antiplatelet Use in Ischemic Stroke. Ann Pharmacother 2022; 56: 1159–73.

3. Serebruany VL, Kim MH, Hanley DF. Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial. Int J Stroke 2016; 11: 614–7.

4. De Luca C, Colangelo AM, Alberghina L, et al. Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Front Cell Neurosci 2018; 12: 459.

5. Sokolova E, Reiser G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost 2008; 100: 576–81.

6. Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323–7.

7. Suri MFK, Yamagishi K, Aleksic N, et al. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc Dis 2010; 29: 497–502.

8. Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113–7.

9. Undas A, Slowik A, Gissel M, et al. Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. Thromb Res 2011; 128: e62–6.

10. Leung PY, Hurst S, Berny-Lang MA, et al. Inhibition of Factor XII-Mediated Activation

of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Transl Stroke Res 2012; 3: 381–9.

11. Maroney SA, Westrick RJ, Cleuren AC, et al. Tissue factor pathway inhibitor is required for cerebrovascular development in mice. Blood 2021; 137: 258–68.

12. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330: 841–5.

13. Hollister RD, Kisiel W, Hyman BT. Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a Kunitz proteinase inhibitor, in Alzheimer's disease. Brain Res 1996; 728: 13–9.

14. Ziliotto N, Bernardi F, Jakimovski D, et al. Hemostasis biomarkers in multiple sclerosis. Eur J Neurol 2018; 25: 1169–76.

15. Ziliotto N, Lamberti N, Manfredini F, et al. Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors. Mult Scler Relat Disord 2020; 44: 102319.

16. Yang L, Li Y, Bhattacharya A, et al. A plasma proteolysis pathway comprising blood coagulation proteases. Oncotarget 2016; 7: 40919–38.

17. Yang L, Bhattacharya A, Li Y, et al. Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. Oncotarget 2018; 9: 5614–26.

18. Zamolodchikov D, Renné T, Strickland S. The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII. J Thromb Haemost 2016; 14: 995–1007.

19. Begic E, Hadzidedic S, Obradovic S, et al. Increased Levels of Coagulation Factor XI in Plasma Are Related to Alzheimer's Disease Diagnosis. J Alzheimers Dis 2020; 77: 375–86.

20. Sattlecker M, Kiddle SJ, Newhouse S, et al. Alzheimer's disease biomarker discovery

using SOMAscan multiplexed protein technology. Alzheimers Dement 2014; 10: 724–34.

21. Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci 2018; 19: 283–301.

22. Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 2020; 581: 71–6.

23. Ryu JK, Rafalski VA, Meyer-Franke A, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 2018; 19: 1212–23.

24. Ahn HJ, Glickman JF, Poon KL, et al. A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med 2014; 211: 1049–62.

25. Chen Z-L, Revenko AS, Singh P, et al. Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice. Blood 2017; 129: 2547–56.

26. Shnerb Ganor R, Harats D, Schiby G, et al. Elderly apolipoprotein E-/- mice with advanced atherosclerotic lesions in the aorta do not develop Alzheimer's disease-like pathologies. Mol Med Rep 2018; 17: 2488–92.

27. Shnerb Ganor R, Harats D, Schiby G, et al. Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice. Arterioscler Thromb Vasc Biol 2016; 36: 475–81.

28. Ngo ATP, Jordan KR, Mueller PA, et al. Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. J Thromb Haemost 2021; 19: 1001–17.

29. Kaikita K, Takeya M, Ogawa H, et al. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180–8.

30. Morange PE, Simon C, Alessi MC, et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004; 109: 1343–8.

31. Figueras J, Monasterio J, Lidón RM, et al. Lower tissue factor inhibition in patients with ST segment elevation than in patients with non ST elevation acute myocardial infarction. Thromb Res 2012; 130: 458–62.

32. Morange PE, Blankenberg S, Alessi MC, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 5: 475–82.

33. Zhao Y, Yu Y, Shi M, et al. Association study to evaluate TFPI gene in CAD in Han Chinese. BMC Cardiovasc Disord 2017; 17: 188.

34. Naji DH, Tan C, Han F, et al. Significant genetic association of a functional TFPI variant with circulating fibrinogen levels and coronary artery disease. Mol Genet Genomics 2018; 293: 119–28.

35. Opstad TB, Pettersen AA, Weiss T, et al. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J 2010; 8: 7.

36. Moatti D, Haidar B, Fumeron F, et al. A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost 2000; 84: 244–9.

37. Moatti D, Seknadji P, Galand C, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects : impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19: 862–9.

38. Lorentz CU, Verbout NG, Cao Z, et al. Factor XI contributes to myocardial ischemia-reperfusion injury in mice. Blood Adv 2018; 2: 85–8.

39. Kossmann S, Lagrange J, Jäckel S, et al. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. Sci Transl Med [Internet] 2017; 9: . Available from: http://dx.doi.org/10.1126/scitranslmed.aah4923

40. Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017; 129: 1210–5.

41. Doggen CJM, Rosendaal FR, Meijers JCM. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045–51.

42. Butenas S, Undas A, Gissel MT, et al. Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost 2008; 99: 142–9.

43. Salomon O, Steinberg DM, Dardik R, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003; 1: 658–61.

44. Siegerink B, Govers-Riemslag JWP, Rosendaal FR, et al. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 2010; 122: 1854–61.

45. Ząbczyk MT, Hanarz M, Malinowski KP, et al. Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study. Thromb Haemost 2022; 122: 1397–406.

46. Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399: 1383–90.

47. Aronovich A, Nur Y, Shezen E, et al. A novel role for factor VIII and thrombin/PAR1 in regulating hematopoiesis and its interplay with the bone structure. Blood 2013; 122: 2562–71.

48. Borkowska S, Suszynska M, Mierzejewska K, et al. Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs). Leukemia 2014; 28: 2148–54.

49. Gur-Cohen S, Kollet O, Graf C. Regulation of long-term repopulating hematopoietic stem cells by EPCR/PAR1 signaling. Ann N Y Acad Sci [Internet] Wiley Online Library; 2016; . Available from: https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/nyas.13013

50. Nevo N, Zuckerman T, Gur-Cohen S, et al. PAR1 Expression Predicts Clinical G-CSF CD34 HSPC Mobilization and Repopulation Potential in Transplanted Patients. Hemasphere 2019; 3: e288.

51. Nevo N, Ordonez-Moreno L-A, Gur-Cohen S, et al. Enhanced thrombin/PAR1 activity promotes G-CSF- and AMD3100-induced mobilization of hematopoietic stem and progenitor cells via NO upregulation. Leukemia 2021; 35: 3334–8.

52. Fares I, Chagraoui J, Lehnertz B, et al. EPCR expression marks UM171-expanded CD34 cord blood stem cells. Blood 2017; 129: 3344–51.

53. Groeneweg KE, Duijs JMGJ, Florijn BW, et al. Circulating Long Noncoding RNA LNC-EPHA6 Associates with Acute Rejection after Kidney Transplantation. Int J Mol Sci [Internet] 2020; 21: . Available from: http://dx.doi.org/10.3390/ijms21165616

54. Humphreys BD. Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy. Semin Nephrol 2012; 32: 463–70.

55. Lerman LO, Chade AR. Angiogenesis in the kidney: a new therapeutic target? Curr Opin

Nephrol Hypertens 2009; 18: 160–5.

56. Bijkerk R, Duijs JMGJ, Khairoun M, et al. Circulating microRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation. Am J Transplant 2015; 15: 1081–90.

57. Dólleman SC, Agten SM, Spronk HMH, et al. Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity. J Thromb Haemost 2022; 20: 996–1007.

58. Maroney SA, Haberichter SL, Friese P, et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007; 109: 1931–7.

59. Uil M, Hau CM, Ahdi M, et al. Cellular origin and microRNA profiles of circulating extracellular vesicles in different stages of diabetic nephropathy. Clin Kidney J 2021; 14: 358–65.

60. Uil M, Butter LM, Claessen N, et al. Platelet inhibition by ticagrelor is protective against diabetic nephropathy in mice. FASEB J 2020; 34: 13750–61.

61. Cameron-Vendrig A, Reheman A, Siraj MA, et al. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes 2016; 65: 1714–23.

62. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates [Internet]. Clinical Science. 2018. p. 1243–52. Available from: http://dx.doi.org/10.1042/cs20180306

63. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med 2015; 278: 483–93.

64. Quillard T, Franck G, Mawson T, et al. Mechanisms of erosion of atherosclerotic plaques. Curr Opin Lipidol 2017; 28: 434–41.

65. Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis. Circ Res

2014; 114: 1757–71.

66. Viola J, Soehnlein O. Atherosclerosis - A matter of unresolved inflammation. Semin Immunol 2015; 27: 184–93.

67. True C, Dean T, Takahashi D, et al. Maternal High-Fat Diet Effects on Adaptations to Metabolic Challenges in Male and Female Juvenile Nonhuman Primates. Obesity 2018; 26: 1430–8.

68. Evans BR, Yerly A, van der Vorst EPC, et al. Inflammatory Mediators in Atherosclerotic Vascular Remodeling. Front Cardiovasc Med 2022; 9: 868934.

69. Jiang H, Zhou Y, Nabavi SM, et al. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. Front Cardiovasc Med 2022; 9: 925923.

70. Silasi R, Keshari RS, Lupu C, et al. Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death. Blood Adv 2019; 3: 658–69.

71. Puy C, Ngo ATP, Pang J, et al. Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI). Arterioscler Thromb Vasc Biol 2019; 39: 1390–401.

72. Endler G, Marsik C, Jilma B, et al. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007; 5: 1143–8.

73. Cooley BC. The dirty side of the intrinsic pathway of coagulation. Thromb Res 2016; 145: 159–60.

74. Juang LJ, Mazinani N, Novakowski SK, et al. Coagulation factor XII contributes to hemostasis when activated by soil in wounds. Blood Adv 2020; 4: 1737–45.

75. Mailer RK, Rangaswamy C, Konrath S, et al. An update on factor XII-driven vascular inflammation. Biochim Biophys Acta Mol Cell Res 2022; 1869: 119166.

76. de Maat S, Joseph K, Maas C, et al. Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema. Clin Rev Allergy Immunol 2021; 60: 348–56.

77. Scheffel J, Mahnke NA, Hofman ZLM, et al. Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. Nat Commun 2020; 11: 179.

78. Govers-Riemslag JWP, Konings J, Cosemans JMEM, et al. Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis. TH Open 2019; 3: e273–85.

79. Dickeson SK, Kumar S, Sun M-F, et al. A mechanism for hereditary angioedema caused by a lysine 311-to-glutamic acid substitution in plasminogen. Blood 2022; 139: 2816–29.

80. Stavrou EX, Fang C, Bane KL, et al. Factor XII and uPAR upregulate neutrophil functions to influence wound healing. J Clin Invest 2018; 128: 944–59.

81. Burla F, Mulla Y, Vos BE, et al. From mechanical resilience to active material properties in biopolymer networks. Nature Reviews Physics Nature Publishing Group; 2019; 1: 249–63.

82. Litvinov RI, Weisel JW. Fibrin mechanical properties and their structural origins. Matrix Biol 2017; 60-61: 110–23.

83. Vos BE, Martinez-Torres C, Burla F, et al. Revealing the molecular origins of fibrin's elastomeric properties by in situ X-ray scattering. Acta Biomater 2020; 104: 39–52.

84. Wang Y, Kumar S, Nisar A, et al. Probing fibrin's molecular response to shear and tensile deformation with coherent Raman microscopy. Acta Biomater 2021; 121: 383–92.

85. Undas A, Ariëns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88–99.

86. Leong L, Chernysh IN, Xu Y, et al. Clot stability as a determinant of effective factor

VIII replacement in hemophilia A. Res Pract Thromb Haemost 2017; 1: 231–41.

87. Wolberg AS, Allen GA, Monroe DM, et al. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645–55.

88. Plodinec M, Loparic M, Monnier CA, et al. The nanomechanical signature of breast cancer. Nat Nanotechnol 2012; 7: 757–65.

89. Alkarithi G, Duval C, Shi Y, et al. Thrombus Structural Composition in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2021; 41: 2370–83.

90. Staessens S, François O, Brinjikji W, et al. Studying Stroke Thrombus Composition After Thrombectomy: What Can We Learn? Stroke 2021; 52: 3718–27.

91. Karbach SH, Schönfelder T, Brandão I, et al. Gut Microbiota Promote Angiotensin II-Induced Arterial Hypertension and Vascular Dysfunction. J Am Heart Assoc [Internet] 2016; 5: . Available from: http://dx.doi.org/10.1161/JAHA.116.003698

92. Han Y-H, Onufer EJ, Huang L-H, et al. Enterically derived high-density lipoprotein restrains liver injury through the portal vein. Science [Internet] 2021; 373: . Available from: http://dx.doi.org/10.1126/science.abe6729

93. Johnson EL, Heaver SL, Waters JL, et al. Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels. Nat Commun 2020; 11: 2471.

94. Formes H, Bernardes JP, Mann A, et al. The gut microbiota instructs the hepatic endothelial cell transcriptome [Internet]. iScience. 2021. p. 103092. Available from: http://dx.doi.org/10.1016/j.isci.2021.103092

95. Jäckel S, Kiouptsi K, Lillich M, et al. Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2 [Internet]. Blood. 2017. p. 542–53. Available from: http://dx.doi.org/10.1182/blood-2016-11-754416

96. Ascher S, Wilms E, Pontarollo G, et al. Gut Microbiota Restricts NETosis in Acute

Mesenteric Ischemia-Reperfusion Injury. Arterioscler Thromb Vasc Biol 2020; 40: 2279–92.

97. Ascher S, Reinhardt C. The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol 2018; 48: 564–75.

98. Zhu W, Gregory JC, Org E, et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell 2016; 165: 111–24.

99. Kappel BA, De Angelis L, Heiser M, et al. Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. Mol Metab 2020; 36: 100976.

100. Stepankova R, Tonar Z, Bartova J, et al. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb 2010; 17: 796–804.

101. Lindskog Jonsson A, Caesar R, Akrami R, et al. Impact of Gut Microbiota and Diet on the Development of Atherosclerosis in Apoe-/- Mice. Arterioscler Thromb Vasc Biol 2018; 38: 2318–26.

102. Kiouptsi K, Jäckel S, Pontarollo G, et al. The Microbiota Promotes Arterial Thrombosis in Low-Density Lipoprotein Receptor-Deficient Mice. MBio [Internet] 2019; 10: . Available from: http://dx.doi.org/10.1128/mBio.02298-19

103. Kasahara K, Krautkramer KA, Org E, et al. Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol 2018; 3: 1461–71.

104. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57–63.

105. Wang Z, Roberts AB, Buffa JA, et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell 2015; 163: 1585–

95.

106.   Haghikia A, Li XS, Liman TG, et al. Gut Microbiota–Dependent Trimethylamine *N* - Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes [Internet]. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018. p. 2225–35. Available from: http://dx.doi.org/10.1161/atvbaha.118.311023

107.   Witkowski M, Witkowski M, Friebel J, et al. Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis [Internet]. Cardiovascular Research. 2022. p. 2367–84. Available from: http://dx.doi.org/10.1093/cvr/cvab263

108.   Kiouptsi K, Jäckel S, Wilms E, et al. The Commensal Microbiota Enhances ADP-Triggered Integrin αIIbβ3 Activation and von Willebrand Factor-Mediated Platelet Deposition to Type I Collagen [Internet]. International Journal of Molecular Sciences. 2020. p. 7171. Available from: http://dx.doi.org/10.3390/ijms21197171

109.   Zhang X, Zhang X, Tong F, et al. Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment. Elife [Internet] 2022; 11: . Available from: http://dx.doi.org/10.7554/eLife.70240

110.   Vieira-Silva S, Falony G, Belda E, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 2020; 581: 310–5.

111.   Harper A, Vijayakumar V, Ouwehand AC, et al. Viral Infections, the Microbiome, and Probiotics. Front Cell Infect Microbiol 2020; 10: 596166.

112.   Hussain I, Cher GLY, Abid MA, et al. Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential. Front Immunol 2021; 12: 765965.

113.   Sun Z, Song Z-G, Liu C, et al. Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients. BMC Med 2022;

20: 24.

114.   Du X, Ley R, Buck AH. MicroRNAs and extracellular vesicles in the gut: new host modulators of the microbiome? microLife 2021; 2: uqab010.

115.   Konkoth A, Saraswat R, Dubrou C, et al. Multifaceted role of extracellular vesicles in atherosclerosis. Atherosclerosis 2021; 319: 121–31.

116.   Zuo T, Wu X, Wen W, et al. Gut Microbiome Alterations in COVID-19 [Internet]. Genomics, Proteomics & Bioinformatics. 2021. p. 679–88. Available from: http://dx.doi.org/10.1016/j.gpb.2021.09.004

117.   Goeijenbier M, van Wissen M, van de Weg C, et al. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol 2012; 84: 1680–96.

118.   Raadsen M, Du Toit J, Langerak T, et al. Thrombocytopenia in Virus Infections. J Clin Med Res [Internet] 2021; 10: . Available from: http://dx.doi.org/10.3390/jcm10040877

119.   Mairuhu ATA, Mac Gillavry MR, Setiati TE, et al. Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis 2003; 3: 33–41.

120.   Goeijenbier M, van Gorp ECM, Van den Brand JMA, et al. Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. BMC Microbiol 2014; 14: 134.

121.   Keller TT, Mairuhu ATA, de Kruif MD, et al. Infections and endothelial cells. Cardiovasc Res 2003; 60: 40–8.

122.   Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35: 545–54.

123.   Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 2004; 114: 321–7.

124. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698–704.

125. Levi M, van der Poll T, Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med 2012; 70: 114–20.

126. van der Poll T, de Boer JD, Levi M. The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 2011; 24: 273–8.

127. van Gorp EC, Suharti C, ten Cate H, et al. Review: infectious diseases and coagulation disorders. J Infect Dis 1999; 180: 176–86.

128. Van Gorp ECM, Setiati TE, Mairuhu ATA, et al. Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever. J Med Virol 2002; 67: 549–54.

129. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35: 2191–5.

130. Miller HC, Stephan M. Hemorrhagic varicella: a case report and review of the complications of varicella in children. Am J Emerg Med 1993; 11: 633–8.

131. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31: 256–63.

132. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004; 10: S110–21.

133. Megy K, Downes K, Simeoni I, et al. Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. J Thromb Haemost 2019; 17: 1253–60.

134. Ver Donck F, Labarque V, Freson K. Hemostatic phenotypes and genetic disorders. Res Pract Thromb Haemost 2021; 5: e12637.

135. Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood 2019; 134: 2082–91.

136. Megy K, Downes K, Morel-Kopp M-C, et al. GoldVariants, a resource for sharing

rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis. J Thromb Haemost 2021; 19: 2612–7.

137.   Turro E, Astle WJ, Megy K, et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature 2020; 583: 96–102.

138.   Westbury SK, Turro E, Greene D, et al. Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Med 2015; 7: 36.

139.   Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. JACC Cardiovasc Interv 2020; 13: 606–17.

140.   Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011; 12: 487–97.

141.   Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213–60.

142.   Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.

143.   Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.

144.   Vranckx P, Leonardi S, Tebaldi M, et al. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. Eur Heart J 2014; 35: 2524–9.

145. Vranckx P, White HD, Huang Z, et al. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am Coll Cardiol 2016; 67: 2135–44.

146. Postula M, Janicki PK, Rosiak M, et al. Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes. Med Sci Monit 2013; 19: 394–408.

147. Gurbel PA, Rout A, Tantry US. Pharmacogenetic considerations in antiplatelet therapy. Expert Review of Precision Medicine and Drug Development Taylor & Francis; 2020; 5: 235–8.

148. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487–96.

149. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553–60.

150. Ancrenaz V, Daali Y, Fontana P, et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010; 11: 667–77.

151. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92–9.

152. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354–62.

153. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA

2010; 303: 754–62.

154.   Harmsze, Werkum. Besides CYP2C19* 2, the variant allele CYP2C9* 3 is associated

with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy ….

Pharmacogenetics [Internet]. Available from:

https://journals.lww.com/jpharmacogenetics/FullText/2010/01000/Besides_CYP2C19_2,

_the_variant_allele_CYP2C9_3_is.3.aspx

155.   Hulot J-S, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function

polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Blood 2006; 108: 2244–7.

156.   Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 and CYP2C9*3

alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31:

3046–53.

157.   Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation

Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.

Clin Pharmacol Ther [Internet] 2022; . Available from:

http://dx.doi.org/10.1002/cpt.2526

158.   Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 Genotype on Ischemic

Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. JACC Cardiovasc

Interv 2021; 14: 739–50.

159.   Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12

Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After

Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.

JAMA 2020; 324: 761–71.

160.   Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of

acute coronary syndromes in patients presenting without persistent ST-segment

elevation. Eur Heart J 2021; 42: 1289–367.

161.   Beitelshees AL, Thomas CD, Empey PE, et al. CYP2C19 Genotype-Guided

Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical

Settings. J Am Heart Assoc American Heart Association; 2022; 11: e024159.

162.   Pan Y, Chen W, Xu Y, et al. Genetic Polymorphisms and Clopidogrel Efficacy for

Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-

Analysis. Circulation 2017; 135: 21–33.

163.   Wang Y, Meng X, Wang A, et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-

of-Function Carriers with Stroke or TIA. N Engl J Med 2021; 385: 2520–30.

164.   Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal -

Full Cohort Analysis. N Engl J Med 2017; 377: 431–41.

165.   Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of

anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;

19: 446–51.

166.   Sheffield WP, Lambourne MD, Eltringham-Smith LJ, et al. γT -S195A thrombin

reduces the anticoagulant effects of dabigatran in vitro and in vivo. J Thromb Haemost

2014; 12: 1110–5.

167.   Jourdi G, Gouin-Thibault I, Siguret V, et al. FXa-α2-Macroglobulin Complex

Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo. Thromb

Haemost 2018; 118: 1535–44.

168.   Thalji NK, Ivanciu L, Davidson R, et al. A rapid pro-hemostatic approach to

overcome direct oral anticoagulants. Nat Med 2016; 22: 924–32.

169.   Parsons-Rich D, Hua F, Li G, et al. Phase 1 dose-escalating study to evaluate the

safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant

(FXaI16L). J Thromb Haemost 2017; 15: 931–7.

170. Verhoef D, Visscher KM, Vosmeer CR, et al. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. Nat Commun 2017; 8: 528.

171. von Drygalski A, Cramer TJ, Bhat V, et al. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. J Thromb Haemost 2014; 12: 363–72.

172. von Drygalski A, Bhat V, Gale AJ, et al. An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms. Blood Adv 2020; 4: 3716–27.

173. Ansell J, Laulicht BE, Bakhru SH, et al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Blood 2021; 137: 115–25.

174. Ansell J, Bakhru S, Laulicht BE, et al. Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. Eur Heart J 2022; 43: 985–92.

175. Caruso C, Lam WA. Point-of-Care Diagnostic Assays and Novel Preclinical Technologies for Hemostasis and Thrombosis. Semin Thromb Hemost 2021; 47: 120–8.

176. Boender J, Kruip MJHA, Leebeek FWG. A diagnostic approach to mild bleeding disorders. J Thromb Haemost 2016; 14: 1507–16.

177. Moenen FCJI, Vries MJA, Nelemans PJ, et al. Screening for platelet function disorders with Multiplate and platelet function analyzer. Platelets 2019; 30: 81–7.

178. Panova-Noeva M, van der Meijden PEJ, Ten Cate H. Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets. J Clin Med Res [Internet] 2019; 9: . Available from: http://dx.doi.org/10.3390/jcm9010092

179. Branchford BR, Ng CJ, Neeves KB, et al. Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis. Thromb Res 2015; 136: 13–9.

180. de Breet CPDM, Zwaveling S, Vries MJA, et al. Thrombin Generation as a Method to

Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy. Front Cardiovasc Med 2021; 8: 679934.

181. Hulshof A-M, Olie RH, Vries MJA, et al. Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention. Front Cardiovasc Med 2021; 8: 788137.

182. Brouns SLN, van Geffen JP, Heemskerk JWM. High-throughput measurement of human platelet aggregation under flow: application in hemostasis and beyond. Platelets 2018; 29: 662–9.

183. Qiu Y, Ahn B, Sakurai Y, et al. Microvasculature-on-a-chip for the long-term study of endothelial barrier dysfunction and microvascular obstruction in disease. Nat Biomed Eng 2018; 2: 453–63.

184. Sakurai Y, Hardy ET, Ahn B, et al. A microengineered vascularized bleeding model that integrates the principal components of hemostasis. Nat Commun 2018; 9: 509.

185. Mangin PH, Gardiner EE, Nesbitt WS, et al. In vitro flow based systems to study platelet function and thrombus formation: Recommendations for standardization: Communication from the SSC on Biorheology of the ISTH. J Thromb Haemost 2020; 18: 748–52.

186. Sniderman J, Monagle P, Annich GM, et al. Hematologic concerns in extracorporeal membrane oxygenation. Res Pract Thromb Haemost 2020; 4: 455–68.

187. Olson SR, Murphree CR, Zonies D, et al. Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review. ASAIO J 2021; 67: 290–6.

188. Vaquer S, de Haro C, Peruga P, et al. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care 2017; 7: 51.

189.   Noah MA, Peek GJ, Finney SJ, et al. Referral to an Extracorporeal Membrane Oxygenation Center and Mortality Among Patients With Severe 2009 Influenza A(H1N1) [Internet]. JAMA. 2011. p. 1659. Available from: http://dx.doi.org/10.1001/jama.2011.1471

190.   Pham T, Combes A, Rozé H, et al. Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med 2013; 187: 276–85.

191.   Aubron C, DePuydt J, Belon F, et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation [Internet]. Annals of Intensive Care. 2016. Available from: http://dx.doi.org/10.1186/s13613-016-0196-7

192.   Brogan TV, Thiagarajan RR, Rycus PT, et al. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database [Internet]. Intensive Care Medicine. 2009. p. 2105–14. Available from: http://dx.doi.org/10.1007/s00134-009-1661-7

193.   Aubron C, Cheng AC, Pilcher D, et al. Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. Crit Care 2013; 17: R73.

194.   Murphy DA, Hockings LE, Andrews RK, et al. Extracorporeal Membrane Oxygenation—Hemostatic Complications [Internet]. Transfusion Medicine Reviews. 2015. p. 90–101. Available from: http://dx.doi.org/10.1016/j.tmrv.2014.12.001

195.   Nguyen TP, Phan XT, Nguyen TH, et al. Major Bleeding in Adults Undergoing Peripheral Extracorporeal Membrane Oxygenation (ECMO): Prognosis and Predictors. Crit Care Res Pract 2022; 2022: 5348835.

196.   Cashen K, Meert K, Dalton H. Anticoagulation in Neonatal ECMO: An Enigma Despite a Lot of Effort! Front Pediatr 2019; 7: 366.

197. Hunt BJ, Parratt RN, Segal HC, et al. Activation of Coagulation and Fibrinolysis During Cardiothoracic Operations [Internet]. The Annals of Thoracic Surgery. 1998. p. 712–8. Available from: http://dx.doi.org/10.1016/s0003-4975(97)01345-3

198. Heilmann C, Geisen U, Beyersdorf F, et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012; 38: 62–8.

199. Palatianos GM, Foroulis CN, Vassili MI, et al. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit. Ann Thorac Surg 2003; 76: 129–35.

200. Bembea MM, Annich G, Rycus P, et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14: e77–84.

201. Paden ML, Conrad SA, Rycus PT, et al. Extracorporeal Life Support Organization Registry Report 2012. ASAIO J 2013; 59: 202–10.

202. Kim J, Koo B-K, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol 2020; 21: 571–84.

203. Bock C, Boutros M, Camp JG, et al. The Organoid Cell Atlas. Nat Biotechnol 2021; 39: 13–7.

204. Veninga V, Voest EE. Tumor organoids: Opportunities and challenges to guide precision medicine. Cancer Cell 2021; 39: 1190–201.

205. Khan AO, Reyat JS, Hill H, et al. Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. Cardiovasc Res [Internet] 2022; . Available from: http://dx.doi.org/10.1093/cvr/cvac097

206. Khan AO, Colombo M, Reyat JS, et al. Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies

[Internet]. bioRxiv. 2022 [cited 2022 Sep 11]. p. 2022.03.14.483815. Available from: https://www.biorxiv.org/content/biorxiv/early/2022/03/16/2022.03.14.483815

207. Campello E, Spiezia L, Adamo A, et al. Thrombophilia, risk factors and prevention. Expert Rev Hematol 2019; 12: 147–58.

208. Castoldi E, Hézard N, Mourey G, et al. Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon) [Internet]. Journal of Thrombosis and Haemostasis. 2021. p. 1186–99. Available from: http://dx.doi.org/10.1111/jth.15274

209. Simioni P, Castoldi E, Lunghi B, et al. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005; 106: 2363–5.

210. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361: 1671–5.

211. Wu W, Xiao L, Wu X, et al. Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis. Haematologica 2021; 106: 264–8.

212. Simioni P, Cagnin S, Sartorello F, et al. Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. Blood 2021; 137: 2383–93.

213. Takagi Y, Murata M, Kozuka T, et al. Missense mutations in the gene encoding prothrombin corresponding to Arg596 cause antithrombin resistance and thrombomodulin resistance [Internet]. Thrombosis and Haemostasis. 2016. p. 1022–31. Available from: http://dx.doi.org/10.1160/th16-03-0223

214. Djordjevic, Kovac, Miljic, et al. A novel prothrombin mutation in two families with prominent thrombophilia–the first cases of antithrombin resistance in a Caucasian population. J Thromb Circ Open Access [Internet]. Available from:

https://www.academia.edu/download/50650277/jth123671.pdf

215.   Sivasundar S, Oommen AT, Prakash O, et al. Molecular defect of 'Prothrombin Amrita': substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis Elsevier BV; 2013; 50: 182–3.

216.   Bulato C, Radu CM, Campello E, et al. New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arterioscler Thromb Vasc Biol 2016; 36: 1022–9.

217.   Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, et al. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009; 7: 247–54.

218.   Schutgens REG, Klamroth R, Pabinger I, et al. Management of atrial fibrillation in people with haemophilia – a consensus view by the ADVANCE Working Group. Haemophilia John Wiley & Sons, Ltd; 2014; 20: e417–20.

219.   Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016; 128: 178–84.

220.   Ferraris VA, Boral LI, Cohen AJ, et al. Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev 2015; 23: 53–68.

221.   Shapiro S, Makris M. Haemophilia and ageing. Br J Haematol 2019; 184: 712–20.

222.   Guillet B, Cayla G, Lebreton A, et al. Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry. Thromb Haemost 2021; 121: 287–96.

223.   de Koning MLY, Fischer K, de Laat B, et al. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists. J Thromb Haemost 2017; 15: 868–75.

224.   van den Ham HA, Souverein PC, Klungel OH, et al. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple

population-based cohort studies. Pharmacoepidemiol Drug Saf Wiley; 2021; 30: 1339–52.

225. Nagy M, Perrella G, Dalby A, et al. Flow studies on human GPVI-deficient blood under coagulating and noncoagulating conditions. Blood Adv 2020; 4: 2953–61.

226. Voors-Pette C, Lebozec K, Dogterom P, et al. Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol 2019; 39: 956–64.

227. Cooper N, Altomare I, Thomas MR, et al. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther Adv Hematol 2021; 12: 20406207211010875.

228. Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019; 129: 12–23.

229. Nicolson PL, Welsh JD, Chauhan A, et al. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors. Platelets. 2020. p. 685–90.

230. Toh C-H, Wang G, Parker AL. The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. Clin Med 2022; 22: 140–4.

231. Smith CW, Montague SJ, Kardeby C, et al. Antiplatelet drugs block platelet activation by VITT patient serum. Blood 2021; 138: 2733–40.

232. Nicolson PLR, Nock SH, Hinds J, et al. Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica 2021; 106: 208–19.

233. Tillman BF, Gruber A, McCarty OJT, et al. Plasma contact factors as therapeutic targets. Blood Rev 2018; 32: 433–48.

234. Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684–92.

235.   Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981–9.

236.   Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372: 232–40.

237.   Verhamme P, Yi BA, Segers A, et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med 2021; 385: 609–17.

238.   Weitz JI, Strony J, Ageno W, et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med [Internet] 2021; . Available from: http://dx.doi.org/10.1056/NEJMoa2113194

239.   Liuzzo G, Patrono C. A novel inhibitor of Factor XIa as potential haemostasis-sparing anticoagulant for patients with atrial fibrillation. Eur Heart J 2022; 43: 2354–5.

240.   Rao SV, Kirsch B, Bhatt DL, et al. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction. Circulation [Internet] 2022; . Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061612

241.   Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet [Internet] 2022; . Available from: http://dx.doi.org/10.1016/S0140-6736(22)01588-4

242.   Thachil J. Lessons learnt from COVID-19 coagulopathy. EJHaem Wiley; 2021; 2: 577–84.

243.   Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7: e438–40.

244.   Thachil J, Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung

Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism? Semin Thromb Hemost 2020; 46: 777–80.

245.   Thachil J. All those D-dimers in COVID-19. J. Thromb. Haemost. 2020. p. 2075–6.

246.   Thachil J. What do monitoring platelet counts in COVID-19 teach us? J. Thromb. Haemost. 2020. p. 2071–2.

247.   Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 1023–6.

248.   Lacroix, Sabatier, Mialhe, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells …. Blood, The Journal [Internet]. Available from: https://ashpublications.org/blood/article-abstract/110/7/2432/103622

249.   Dejouvencel T, Doeuvre L, Lacroix R, et al. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood 2010; 115: 2048–56.

250.   Cointe S, Vallier L, Esnault P, et al. Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock. Blood 2022; 139: 2377–91.

251.   Lacroix R, Plawinski L, Robert S, et al. Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis [Internet]. Haematologica. 2012. p. 1864–72. Available from: http://dx.doi.org/10.3324/haematol.2012.066167

252.   Lacroix R, Dubois C, Leroyer AS, et al. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost 2013; 11 Suppl 1: 24–35.

253.   Vallier L, Cointe S, Lacroix R, et al. Microparticles and Fibrinolysis. Semin Thromb Hemost 2017; 43: 129–34.

254.   Cointe S, Harti Souab K, Bouriche T, et al. A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance. J

Extracell Vesicles 2018; 7: 1494482.

255.   Vallier L, Bouriche T, Bonifay A, et al. Increasing the sensitivity of the human microvesicle tissue factor activity assay. Thromb Res 2019; 182: 64–74.

256.   Franco C, Lacroix R, Vallier L, et al. A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids. Thromb Res 2020; 196: 414–24.